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INTRODUCITON 
Liver is a large, homogenous organ and therefore is well suited for 
evaluation by many imaging techniques. Liver tumors in the adults are one of 
the common lesions in day today practice. Common adult hepatic tumors 
include hepatocellular carcinoma, metastases and hemangiomas. 45 
Hepatocellular carcinoma (HCC) represents 5% of all cancers and is the 
dominant cause of death in compensated cirrhosis. HCC incidence is increasing 
worldwide because of increasing HBV and HCV infection. HCC accounts for 
85% of primary liver cancer. Most patients die within one year after diagnosis. 
Survival is dependent on tumor size and associated disease at the time of 
diagnosis. So, early detection of HCC is very important to prolong the survival. 
HCC is more common in` males in the age group 30 to 60 years.7  
Liver provides fertile soil in which metastases can establish, not only 
because of rich, dual blood supply but also because of humoral factors that 
promote cell growth. (The blood supply of liver is exceeded only by that of the 
lung, in terms of blood flow per minute). Liver is the most commonly involved 
organ by metastatic disease, after the lymphnodes. The liver may be the site of 
metastases for virtually any primary neoplasm. So, patients with any malignant 
neoplasm especially with primary tumors of colon, stomach, pancreas, breast, 
lung and eye should be intensely followed up with ultrasound and if any lesion 
is detected, colour doppler can be utilized for early diagnosis and treatment.22  
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Hemangiomas are the most common benign liver tumors. Reported 
incidence of hepatic hemangiomas is 2%. The prevalence at necropsy is as high 
as 7.4%. Most hepatic hemangiomas are diagnosed at 30 to 50 years with 
females more affected than males.45  
The study of liver tumor is particularly challenging. In many cases, a 
preoperative diagnosis may be achieved with appropriate combination of 
imaging techniques in a purely noninvasive fashion. This is important because 
many adults have benign nonsurgical hepatic lesions such as hemangiomas.45 
There are several imaging modalities to evaluate focal liver lesions 
starting from plain radiograph, USG and doppler, CT, MRI, angiography and 
nuclear medicine techniques. Ultrasound and doppler is the initial, noninvasive, 
easily available modality to characterize focal liver lesions followed by CECT 
or MRI. Scintigraphy done for selected cases. Angiogram is done prior to 
embolization.33    
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              AIM 
1)To characterize the colour doppler USG features of common adult 
hepatic tumors hepatocellular carcinoma, metastases and hemangiomas 
more than 2 cm in size with HPE and CECT correlation 
2) To asses the sensitivity, specificity and accuracy of colour doppler 
ultrasound in differentiating HCCs, metastases and hemangiomas.  
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REVIEW OF LITERATURE 
Normal anatomy 
The liver is the largest abdominal organ, weighing 1400 to 1600 g. It occupies 
most of the right upper quadrant in the normal adult. It is bordered medially 
by the stomach, duodenum and transverse colon; inferiorly by the hepatic 
flexure of the colon; posteriorly by the right adrenal gland and kidney; and 
superiorly, ventrally, and laterally by the diaphragm. It is covered by 
peritoneum except in the region of the gallbladder fossa, the fossa for the 
inferior vena cava, and the bare area. In the bare area, the liver is in direct 
contact with the diaphragm without intervening peritoneum. This region is 
demarcated by the right lobe supporting structures: the superior and inferior 
coronary ligaments. These ligaments fuse laterally to become triangular 
ligament. The left lobe is supported from the diaphragm by the left coronary 
ligament, which is contiguous with the falciform ligament. The falciform 
ligament is a thin fibrous sheet containing the ligamentum teres, which extends 
from the umbilicus to the superior surface of the liver.45 
On the right, the coronary ligament separates the Morison pouch (right 
posterior subhepatic space) from the right subphrenic space. The left coronary 
ligament divides the left subphrenic space into an anterior and a posterior 
compartment. The falciform ligament separates the right subphrenic space 
from the left subhepatic space.  
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The gastrohepatic ligament (lesser omentum) connects the liver and 
stomach. The free edge of lesser omentum (hepatoduodenal ligament) contains 
the common bile duct, hepatic artery, portal vein, nerves and lymphatics. 
Vascular Anatomy 
The liver receives 15 to 20% of the cardiac output and constitutes a significant 
reservoir for blood. The liver has a dual blood supply: the hepatic artery, which 
provides systemic arterial circulation, and the portal vein which returns blood 
from the spleen and gut. These two vascular inflows have different pressures, 
flow rates and compositions. Arterial flow is primarily nutritive and provides 
about 20% of the blood supply; the remainder is supplied by the mesenteric 
portal drainage, which is a consequence of gastrointestinal functional activity. 
The relative contribution of blood flow to the liver by the arterial and portal 
systems depends on a number of factors: hormones, neural stimulation 
(sympathetic, vagal), nutritional state (including fasting or postprandial), and 
the presence of hepatic parenchymal disease.33  
Hepatic Artery 
The celiac artery typically gives rise to the common hepatic, splenic and left 
gastric arteries at the level of T12-L1. The common hepatic artery courses 
along the upper border of the pancreatic head, anteriorly and to the right, 
behind the posterior layer of peritoneum of the lesser sac. It gives off the 
gastroduodenal artery and at upper margin of the duodenum the proper 
hepatic artery enters the subperitoneal space of the hepatoduodenal ligament. 
It ascends to the liver anterior to the portal vein and medial to the common bile 
 11
duct. After entering the porta hepatis, the proper hepatic artery divides into a 
right, a left and occasionally a middle hepatic artery. The right lobe is supplied 
by the right hepatic artery, the medial segment of the left lobe is supplied by the 
middle hepatic artery augmented by the branches of the left hepatic artery and 
the lateral segment of left lobe receives blood from left hepatic artery. Branches 
of the right hepatic artery nourish the caudate lobe, but in some cases the left 
or even middle hepatic artery contributes. The right hepatic artery also gives 
off the cystic artery which supplies the gallbladder.45  
The vascular schema just described is present in only 55% of patients. 
Normal variants include (1)the right hepatic artery partially(18%) or 
completely (14%) replaced by superior mesenteric artery; (2)the entire hepatic 
artery arising from the superior mesenteric artery (2 to 4%); (3)the left hepatic 
artery having a partially or totally replaced origin from the left gastric artery 
(18% to 25%); and (4)the left hepatic artery giving rise to the middle hepatic 
artery in 45% of patients.  
Portal Vein 
The main portal vein arises behind the pancreatic neck at the junction of the 
splenic and superior mesenteric veins. The main portal vein courses to the right 
and superiorly in the hepatoduodenal ligament, along with the hepatic artery 
and common bile duct, anterior to the foramen of Winslow.  At the porta 
hepatis, the portal vein divides into right and left branches. The right portal 
vein courses horizontally before bifurcating into anterior and posterior 
branches. The left portal vein is shorter as it ascends anterior to caudate lobe 
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before it courses ventrally to the left intersegmental fissure, where it divides 
into branches supplying the medial and lateral segments of the left hepatic lobe. 
The ligamentum teres (umbilical vein remnant) inserts into the anterior margin 
of the left portal vein. In embryonic life, blood in the umbilical vein empties 
into the left portal vein and much of it is shunted to the inferior vena cava and 
systemic circulation through the ductus venosus.33 
Hepatic Veins 
The hepatic veins reside between the hepatic segments and lobes. The right 
hepatic vein is usually the largest and courses obliquely between the anterior 
and posterior segments of the right lobe. The middle hepatic vein is in between 
superior aspect of the right and left lobes. The left hepatic vein courses between 
the medial and lateral segments of the left lobe. All these veins drain obliquely 
and superiorly into the inferior vena cava, near its entrance into the right 
atrium. The right hepatic vein usually enters the inferior vena cava separately 
from the middle and left hepatic veins. The last two veins typically form a 
common trunk as they enter the vena cava.45  
Lobar and Segmental Anatomy 
The segmental anatomy of the liver is eloquently depicted on cross-sectional 
imaging. Delineation of this anatomy is essential for the localization of focal hepatic 
pathology before surgical, angiographic or percutaneous intervention. Hepatic 
segmental topography is best appreciated radiographically by identification of the 
vascular and fissural anatomy. The portal venous, hepatic arterial and biliary 
systems travel together within hepatic segments and lobes (intrasegmental). The 
main hepatic veins course between segments and lobes (intersegmental).45 
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The right hepatic vein separates the posterior and anterior segments of 
the right lobe. The middle hepatic vein superiorly and the interlobar fissure 
inferiorly separate the right and left lobes of the liver. The medial and lateral 
segments of the left hepatic lobe are divided by three readily discernible 
structures: the ligamentum teres (inferiorly), the ascending portion of the left 
portal vein and the left hepatic vein (superiorly).  
Advances in surgical techniques and percutaneous intervention have 
popularized the use of the subsegmental anatomic classification of Couinaud, 
with the modification of Bismuth and colleagues, to define hepatic location 
more precisely. In this system, the liver is divided into one segment and eight 
subsegments. Segment 1 is the caudate lobe. The well-known vertical divisions 
along the planes of hepatic veins are maintained, but each segment is further 
divided into superior and inferior subsegments by a transverse fissure (a plane 
through the right and left portal veins). The subsegments are numbered in a 
clockwise fashion when viewing the liver in the frontal projection except for 
segment 4a.  
The caudate lobe is central hepatic lobe that has certain unique features. 
The anterior border of the caudate lobe is separated from the lateral segment of 
the left lobe by the fissure for the ligamentum venosum. The pars transversa of 
the left portal vein resides at the apex of this fissure. Fat in this fissure often 
communicates with fat in the fissure for ligamentum teres. Posteriorly caudate 
lobe is bordered by the inferior vena cava. Inferiorly caudate lobe forms the 
superior margin of foramen of Winslow.45 
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RADIOLOGIC TECHNIQUES 
Plain Films 
The plain abdominal radiograph usually reveals little detail of hepatic structure 
because of the homogenous, soft tissue density of the liver. The superior margin 
of the liver is clearly depicted by the diaphragm and lung. The other borders 
are less well defined. The presence of hepatic calcification should be carefully 
sought when evaluating plain abdominal radiograph.33  
Ultrasound 
The liver is ideally located in the right upper quadrant for sonographic 
evaluation. It has a broad area of contact with the abdominal wall, so that 
bowel gas and intraperitoneal fat are not limiting factors. Sonography is a fast, 
inexpensive and safe means of evaluating the liver noninvasively, particularly 
in thin patients. It can be done portably and fast and is inexpensive, safe and 
requires little preparation or cooperation of the patient.5 
The highest frequency transducer possible should be employed. If 
sufficient penetration to the posterior aspect of the liver cannot be obtained 
with a high frequency transducer, a lower frequency transducer should be 
used. The near and far gain settings should be adjusted to give a uniform 
representation of the hepatic parenchyma.    
With real time scanning, the ideal imaging plane can be selected rapidly 
to display normal and pathologic anatomy to allow uncooperative  patients and 
children to be studied more easily and to assess motion to assist identification of 
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bowel. The major disadvantage of real time scanning is a restricted field of 
view, which can be problematic when measuring an enlarged liver. Focal 
lesions are easily identified on the real time study and may be less well 
appreciated on the hard copy films.33  
Examination Techniques 
Hepatic sonography requires meticulous study with active participation of the 
physician. The examination is begun with the patient in the supine position, but 
frequently it is necessary to rotate the patient onto the left side to promote 
descent of the liver below the rib cage. Asking the patient to take in and hold a 
breath or to push out the anterior abdomen also caudally displaces the liver, 
affording better visualization of the hepatic dome. A small footprint transducer 
is helpful in visualizing livers that lie in a subcostal location.5  
The right lobe is examined by scanning lateral to medial in the 
parasagittal plane. The echogenicity of the liver should be compared with that 
of the right kidney and fluid in the Morison pouch should be sought. The right 
portal vein is followed medially until the common hepatic duct is found. The 
inferior vena cava is also seen at this point. More medially, the confluence of 
the right and left portal veins is seen and subsequently the ascending portion of 
the left portal vein. In the transverse plane, from a right subcostal or 
intercostals location with cephalad angulation, the confluence of the hepatic 
veins into the inferior vena cava can be seen. The transducer is then angulated 
sequentially caudally, showing the bifurcation of the portal veins.  
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Sonography is an excellent means of following the course of hepatic and 
portal veins. The portal vein divides at the porta hepatis into right and left 
main branches. The portal veins are anechoic structures with echogenic walls. 
The bile ducts run with the portal veins and are too small to be seen except at 
the hilum, unless they are dilated. The hepatic arteries also run with these 
structures but are usually too small to be seen except with the aid of colour flow 
imaging.5  
The hepatic veins course posteriorly and superiorly through the liver to 
the inferior vena cava. They are intersegmental, whereas portal veins are 
intrasegmental with the exception of the ascending segment of the left portal 
vein. The walls of hepatic veins are usually less echogenic than those of the 
portal veins.  
Normal Size, Shape and Architecture 
Because of the variable size and shape of the liver, the sonographic assessment 
of hepatic size is ultimately subjective; no single method accurately reflects true 
hepatic mass. One method that has been found to be 87% accurate in 
determining the presence or absence of hepatomegaly is to measure the liver in 
two planes. In the midclavicular line, the normal liver measures 10.5 +_1.5 cm 
in longitudinal diameter and 8.1+_1.9 cm in the anterior-posterior projection, 
with 12.6 cm and 11.3 cm being the 95th percentile.45    The reflectivity of 
hepatic parenchyma should be evaluated carefully in each patient. The 
parenchymal echoes of the liver should be relatively even in brightness and 
texture and should be interrupted only by hepatic veins, the portal triads and 
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fissures. The parenchyma echoes appear as moderately short dots or lines. 
Normal parenchyma should be isoechoic in youth, slightly brighter in 30 to 60 
years of age and markedly more echogenic in older patients. In ultrasound we 
have to see for,33 
1)Lesion Size 
2)Shape    
3)Margins 
4)Number 
5)Location (right or left lobe, segments) 
6)Echogenicity 
7)Calcification 
8)Adjacent vessel involvement(portal vein thrombus) 
9)Bile duct dilatation 
10)Liver echoes and architecture (cirrhotic liver) 
11)Regional lymphadenopathy 
12)Ascites 
IntraOperative UltraSound (IOUS) and Laparoscopic US  
IOUS is an important diagnostic tool in patients undergoing hepatic resection 
for colorectal metastases. IOUS allows careful evaluation of the normal liver 
segments to exclude occult metastases in the segments that will be left in situ. 
The high accuracy of IOUS is due to the contact scanning possible with a high-
frequency transducer and color flow Doppler imaging; with this technique, the 
complete organ can be covered without artifact. IOUS depicts 25-35% more 
lesions than does preoperative US. Most significantly, 40% of the lesions 
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detected by means of IOUS are neither visible nor palpable, and would 
presumably have been missed with other means. IOUS has also been shown to 
be a sensitive means of detecting HCC, particularly if US contrast agents are 
used to improve Doppler images.46  
Laparoscopic US is also valuable. It has an advantage over abdominal 
US in that the probe can be used to palpate the surface of the liver. This ability 
aids in the diagnosis of hemangiomas, which can be compressed, unlike solid 
tumors, which cannot.  
Synchronous liver metastases are frequently encountered at surgery for 
GI malignancy; of these, as many as 40% may not have been palpable. IOUS 
enables the detection of 93% of liver metastases, compared with the 51% 
detection rate with preoperative CT and US; 66% are palpable at surgery.  
Doppler Imaging 
Duplex and colour flow Doppler imaging substantially enhance the diagnostic 
capabilities of ultrasound in evaluating the complex circulatory dynamics of the 
liver.56,42 The use of colour doppler in the diagnosis of tumors is based on the 
principle of neovascularity that occur in tumors. The original description of 
arteriographic neovascularity or tumor vascularity is credited to Strickland, 
who reviewed the findings in a series of 33 bone tumors. He described a tumor 
vessel as one that was deployed seemingly without purpose, keeps to no set 
course and shows progressive diminution in caliber. The presence of tumor 
vascularity is often, but not always, associated with an increased number of 
vessels within a tumor, or hypervascularity. Neovascularity may be further 
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characterized as fine or coarse. Histopathologically, these vessels are primitive, 
vascular channels, lacking smooth muscle and often consisting of an endothelial 
layer and connective tissue alone.53  
Two different signal types were identified from malignant tumor. Most 
common tumor signal is high velocity shift, ranging from over 3 KHz to as high 
as 10 KHz (70 to 700 cm/s), with or without enhanced diastolic flow. This type 
of signal is due to presence of arteriovenous shunt in tumors. Doppler 
ultrasound is more sensitive than angiography in the detection of arteriovenous 
shunting. Second type tumor signal consisted of an almost continuous high 
velocity doppler shift, with little or no systolic diastolic variation (low systolic / 
diastolic index); this signal pattern would be expected to originate from a high 
velocity jet into vessels with little or no vascular impedance. Histologic 
examination in these patients will demonstrate the presence of large, thin 
walled, sinusoidal spaces that lacked muscular support. Spectral broadening 
will be seen in tumor signals, in contrast to laminar plug flow seen in normal 
large vessels in which all red blood cells move at the same velocity. Flow 
velocity of 40 cm/s is the optimal threshold value with which benign and 
malignant tumors can be differentiated. This simple, economic doppler 
technique has great potential for noninvasive characterization of tumors.53  
In general, HCCs and metastatic tumors are supplied directly by the 
hepatic artery branches. In these tumors, the small branches supplying the 
tumors are larger than the normal artery, and the branches do not taper 
normally as they approach the lesions and appear to break up into irregular 
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tumor vessels. Arterial branches supplying HCCs tend to show an irregularly 
tortuous extension, and the tumor vessels have widened, sclerosed lumina. 
Stenoses increase the peak systolic velocity, assessed with duplex doppler 
sonography, in large vessels. In normal hepatic arterial branches, peak systolic 
velocities seen in the proximal side generally exceed velocities seen in the distal 
side. If HCCs have irregularly tortuous vessels with widening or narrowing of 
the lumina, elevation of peak systolic velocities attributed to stenotic changes in 
the lumina may be seen in arteries feeding the tumor.37    
Hepatic Artery 
Vessels can be differentiated from bile ducts and from one another by their 
flow characteristics. Thrombosis, reverse flow, aneurysms and fistulas are well 
demonstrated with duplex and colour flow Doppler sonography. The hepatic 
artery  has a Doppler tracing that reflects low impedance characterized by high 
diastolic flow that is seen in normal parenchymal organs. Spectral broadening 
is commonly seen in vessels of this size. Colour flow images may be needed to 
localize the hepatic artery. Doppler sonography is most often used to 
differentiate the hepatic artery from a bile duct in the porta hepatis. The 
intrahepatic branches of the hepatic artery are normally too small to be 
visualized on gray scale sonography. They may undergo compensatory 
dilatation in cirrhosis or become ectatic, simulating the parallel channel sign 
and incorrectly suggesting biliary obstruction. Doppler sonography is useful in 
differentiating the two. Most of the malignant tumors are supplied by the 
hepatic artery, so flow changes in the hepatic artery and its branches are seen 
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in HCCs and metastases. Evaluation of hepatic arterial flow is also important 
for patients who are candidates for or have had liver transplantation.33  
We have to see in Doppler,37  
1)Intralesional flow pattern (pulsatile flow, continuous flow, basket pattern or 
spot pattern, central or peripheral flow) 
2)Intralesional peak systolic velocity 
3)Common hepatic artery peak systolic velocity 
4)Tumor index (intralesional PSV/common hepatic artery PSV) 
5)Portal vein involvement  
Ultrasound Contrast Agents and Harmonic Imaging 
In the liver, the goal of these agents is to increase visualization of slow-flow 
vessels, thereby increasing lesion conspicuity and improving lesion 
characterization. Contrast agents must increase the strength of the echo from 
blood, improving the signal to noise ratio, which determines the detectability  of 
vessels. Agents are injected intravenously, and imaging proceeds immediately 
thereafter. One major drawback of these agents has been the narrow window 
available for scanning after contrast administration. There are two major types 
of ultrasound contrast agents: blood pool agents and agents that act by selective 
uptake into tissues.1  
Blood pool agent uses stabilized microbubbles, which are adsorbed to 
galactose particles and palmitic acid (Levovist). Levovist enhances small vessels 
and improves Doppler signal in the portal vein and has been found to improve 
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the visualization of tumor vessels in hepatocellular carcinoma. Levovist is also 
useful to differentiate between benign hyperechoic lesions and hepatocellular 
carcinoma. The imaging window of levovist is less than 7 minutes. More 
recently developed agents employ low-solubility gases to last longer in the 
bloodstream and increase the returning echo.1  
Harmonic imaging involves modifying the scanner to receive echoes at 
twice the transmitted transducer frequency. This modification detects 
microbubbles as they resonate at their characteristic frequencies.  
Computed Tomography 
The widespread availability of helical CT has significantly changed the way the 
liver is imaged. Helical CT provides several important advantages over 
conventional CT. The most important is its ability to image the entire liver 
rapidly to exploit contrast dynamics and thus improve lesion detectability.45 
Noncontrast Scans 
Noncontrast CT scans of liver are inferior to contrast enhanced studies for 
lesion detection and thus are not routinely performed except in certain specific 
situations. The liver parenchyma is usually homogenous with attenuation 
values ranging between 40 and 70 HU. The attenuation of the liver is variable 
from person to person and may be different from time to time in the same 
individual. The density of the liver parenchyma is greater than that of the blood 
vessels and other intra-abdominal organs. It is usually 7 to 8 HU greater than 
that of the spleen on noncontrast scans.33  
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Contrast Scans 
The goal of contrast enhancement is to improve lesion visibility by increasing 
the relative attenuation difference between the lesion and normal hepatic 
parenchyma. This difference is a fundamental factor in lesion conspicuity and 
characterization. Hepatic enhancement is most dependant on the phase of the 
contrast delivery during which scanning occurs. These phases can be divided 
into vascular(arterial), redistribution(portal venous), equilibrium(delayed) 
phases. Arterial phase taken 20 to 30 seconds after intravenous contrast bolus 
and portal venous phase taken 60 to 90 seconds after intravenous contrast 
bolus.45  
Helical Portal-Venous Phase Scan (Single-Phase Scan) 
This is preferred CT technique for routine hepatic evaluation. With helical CT, 
entire liver can be scanned during peak contrast enhancement, further 
improving diagnostic accuracy. This is accomplished by imaging the liver 
beginning at about 55 to 70 seconds after the start of contrast bolus, depending 
on injection rate. Only 20 seconds are required to image the entire liver. Most 
centers use 150ml of 60% iodinated contrast material injected at a rate of 3 
ml/s or more.33 
Biphasic Helical Scan 
The liver is imaged at two different times after contrast administration. 
Arterial phase is accomplished by scanning 20 to 30 seconds after the initiation 
of contrast administration. A second acquisition is then obtained during the 
portal venous phase of contrast delivery (55 to 65 seconds after contrast 
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initiation). Contrast material is delivered at a faster rate than in portal venous 
scanning (4 to 5 ml/s) and thus the portal venous phase is initiated earlier. 
Biphasic helical scanning has been found especially helpful in hepatocellular 
carcinoma, in which the addition arterial phase scan improves lesion detection 
when compared to portal phase scans alone or CT arterial portography.3  
Computed Tomographic Angiography and Portography 
In this technique, an arterial catheter is placed selectively in the hepatic artery, 
splenic artery or superior mesenteric artery at angiography and the patient is 
transferred for CT imaging. Because of its invasiveness, CTAP is generally 
reserved for patients in whom hepatic resection is contemplated. Hepatic 
arterial injection (computed tomographic hepatic arteriography) produces 
dense enhancement of most lesions because hepatic tumors are predominantly 
supplied by the hepatic artery. Liver metastases that receive primarily arterial 
rather than portal blood appear as low attenuation defects. Because of its high 
sensitivity in detecting focal liver lesions, CTAP has been considered the best 
imaging test for the detection of liver metastases.20  
MR Imaging 
MR imaging is increasingly being used to image the liver. Its role is either as a 
compliment to CT (to characterize a focal lesion or possibly improve sensitivity 
to metastatic disease) or as a first-line study (such as in patients with possible 
metastases or allergy to iodinated contrast material). Many different pulse 
sequences have been used in MR imaging. In general, T1-weighted and T2-
weighted sequences are performed. Contrast agents may be added in certain 
situations.45  
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T1-Weighted Sequences 
On T1-weighted images, the signal intensity of normal liver is greater than that 
of spleen, muscle and kidney and less than that of surrounding fat. Most 
hepatic tumors have a long T1 and thus appear as hypointense lesions on T1-
weighted images. 
T2-Weighted Sequences 
Spin-echo, segmented spin-echo (such as fast or turbo spin-echo) and short tau 
inversion recovery (STIR) sequences can be used to obtain T2-like information. 
Fast spin-echo techniques have shown consistently sharper anatomic detail with 
less respiratory and cardiac motion artifact than conventional  spin-echo 
sequences. Half Fourier acquisition single shot turbo spin echo (HASTE) is 
modification of turbo spin echo allowing for a further reduction in scan time.33  
MRI contrasts  
The contrast agents available for use in liver imaging can be classified into 4 
groups according to their biologic distribution: (1) gadolinium chelates, which 
have an extra cellular distribution; (2) macrophage-monocytic agents targeted 
to the phagocytic system; (3) hepatobiliary agents; and (4) blood pool agents. 
This classification is not strictly accurate because these agents are distributed 
successively or simultaneously to more than one site. Dynamic gadolinium-
enhanced MRI not only improves the detection of focal liver masses but also 
permits the differentiation of benign and malignant lesions.45  
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PET 
Pet is a quantitative physiologic imaging modality using positron emitters, such 
as fluorine-18. The most commonly used radiotracer is 2-fluoro-2-deoxy-D-
glucose (FDG).  FDG-PET proved to be highly sensitive in detecting metastases 
from different primaries. Delbeke and coworkers studied the diagnostic value 
of FDG-PET in hepatic metastases measuring 1 cm or larger, and detected all 
66 metastatic lesions originating from various primaries, such as the colon, 
pancreas, esophagus, sarcoma and parotid. In cases of known solitary hepatic 
metastasis diagnosed by CT, several groups reported discovery of additional 
hepatic metastases by FDG-PET. This is of particular importance in 
preoperative evaluation of solitary hepatic metastasis because detection of 
additional lesions often changes the management.46  
CLASSIFICATION OF LIVER TUMORS:45 
Benign liver tumors and tumor like conditions 
Hepatocellular Origin 
Hepatocellular adenoma 
Hepatocellular hyperplasia 
   Focal nodular hyperplasia 
   Nodular regenerative hyperplasia 
   Macroregenerative nodule(adenomatous hyperplasia) 
Cholangiocellular Origin 
Hepatic cysts 
    Simple hepatic cysts 
    Congenital hepatic fibrosis or polycystic liver disease 
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Benign cystadenoma 
Bile duct adenoma 
Mesenchymal Origin 
Mesenchymal hemartoma 
Hemangioma 
Infantile hemangioendothelioma 
Lymphangioma 
Lipoma, angiolipoma, myelolipoma 
Leiomyoma 
Fibroma 
MALIGNANT TUMORS OF THE LIVER 
PRIMARY  
SECONDARY 
   Lymphoma 
   Metastases 
Primary malignant liver tumors: 
Hepatocellular origin 
Hepatocellular carcinoma 
Clear cell carcinoma 
Giant cell carcinoma 
Childhood HCC 
Carcinosarcoma 
Fibrolamellar carcinoma 
Hepatoblastoma 
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Sclerosing hepatic carcinoma 
Cholangiocellular origin 
  Cholangiocarcinoma 
  Cystadenocarcinoma 
Mesenchymal origin 
Angiosarcoma 
Epetheloid hemangioendothelioma 
Leiomyosarcoma 
Fibrosarcoma 
Malignant fibrous histiocytoma 
Primary lymphoma 
Primary hepatic osteosarcoma 
        Commonest malignant liver tumors encountered in day today practice are 
hepatocellular carcinoma and metastases and the commonest benign tumor is 
hemangioma. 
Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) represents more than 5% of all cancers and is 
the dominant cause of death in patients with compensated cirrhosis. Its 
incidence is increasing worldwide. HCC accounts for up to 85% of primary 
cancers. The tumor is linked to environmental, dietary and lifestyle factors, so 
that its incidence and distribution vary widely among ethnic groups, 
geographic regions and the two sexes.7  
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Incidence and Geographic Distribution 
Internationally: HCC is more common in Asia and Africa than in the United 
States. Internationally, the highest incidence of HCC is in Japan (4-5%). Other 
high-incidence regions include sub-Saharan Africa. In terms of relative 
frequency, HCC ranks as the fifth most common cancer in the world and the 
second most common cancer of the digestive tract, after cancer of the 
stomach.33  
Risk factors45 
Alcohol: As many as 50% of alcoholics may have subclinical HCC at autopsy. 
The risk of HCC is greater once the patient stops drinking alcohol because 
heavy drinkers do not survive long enough to develop cancer. 
Hepatitis B virus: Global incidence of HBV infection is estimated to be 400 
million persons. Chronic infection in the setting of cirrhosis increases the risk 
of HCC 1000-fold. This is the most common cause worldwide and may be 
related to integration of the viral genome into the host DNA. 
Hepatitis C virus: HCV is a global pandemic affecting 170 million persons. 
HCV infection results in a higher rate of chronic infection compared to HBV 
infection (approximately 80% of infected subjects). It has become the most 
common cause of HCC in Japan and Europe, and it also is responsible for 
increased incidence in the United States.  
Hemochromatosis, aflatoxin, primary biliary cirrhosis, androgenic 
steroids, thorotrast, oral contraceptives, and porphyria cutanea tarda. 
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Mortality/Morbidity: Most patients with HCC die within 1 year after diagnosis. 
Survival is dependent on tumor size and associated diseases at the time of 
diagnosis. Patients with cirrhosis have a shorter survival. Surgical cure is 
possible in less than 5% of patients. The causes of death include bleeding 
(variceal, intraperitoneal) and cachexia.  
Race: A high incidence is seen in Japan and Africa.  
Sex: In high-incidence regions of the world (ie, Asia, Africa), the male-to-female 
ratio is approximately 8:1.  
Age: In high-incidence regions of the world (ie, Asia, Africa), patients present 
at age 30-50 years 
Clinical Details 
Clinical presentation varies among high-incidence and low-incidence regions. 
In high-incidence regions (ie, Asia, Africa), clinical presentation of HCC tends 
to be aggressive and includes bleeding, hepatic rupture, and hemoperitoneum. 
In low-incidence regions (ie, Western Hemisphere), clinical presentation of 
HCC tends to be less aggressive and includes symptoms such as fever of 
unknown origin, abdominal pain, malaise, weight loss, and hepatomegaly. 
Jaundice is rare. Liver function tests can be normal. AFP levels may be 
elevated since this protein commonly is produced by HCC.7  
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Pathology 
Based on gross anatomic features, HCC is classified as solitary, multifocal, 
diffuse 
Solitary mass - Often large  
Multifocal or nodular pattern - Multiple nodules  
Diffuse - Multiple, small foci scattered diffusely throughout the liver 
Based on growth patterns, HCC is classified as infiltrative, expanding, 
multinodular or mixed.11  
Lab Studies  
Expect total bilirubin, aspartate aminotransferase (AST), alkaline phosphatase, 
albumin, and prothrombin time to show results consistent with cirrhosis. 
Alpha-fetoprotein (AFP) is elevated in 75% of cases. The level of elevation 
correlates inversely with prognosis. An elevation of greater than 400 ng/mL 
predicts for HCC with specificity greater than 95%. In the setting of a growing 
mass, cirrhosis, and the absence of acute hepatitis, many centers use a level 
greater than 1000 ng/mL as presumptive evidence of HCC (without biopsy).12 
Imaging 
Plain Radiograph: Plain films are nonspecific but may show a mass in the 
upper abdomen if the HCC is large. Rarely calcifications can be detected in 
HCC. 
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Ultrasound and Doppler 
The sonographic appearance of HCC is varied. These lesions are frequently 
hyperechoic, particularly if there is fatty change or marked sinusoidal 
dilatation. Ultrasonography can detect extremely small tumors and when 
combined with serum alpha-fetoprotein assays, serves as an excellent screening 
method for high risk patients with long standing cirrhosis. Sonography, in 
conjunction with colour and duplex Doppler, is an excellent means of 
diagnosing tumor thrombus in the portal and hepatic veins as well as the 
inferior vena cava.5  
Colour Doppler ultrasound has been used to asses the vascularity of 
HCC because HCC tumor nodules are supplied by hepatic artery. Lesions show 
both intratumoral and peritumoral flow. A basket pattern ( a fine blood flow 
network surrounding the tumor nodule) was observed in HCC. In lesions less 
than 2 cm it is difficult to detect the flow pattern. Intralesional pulsatile flow 
with peak systolic velocity (PSV) more than 40 cm/s with relatively normal 
hepatic artery flow is strongly suggestive of HCC.37  
Nuclear Medicine: Nuclear medicine provides relatively nonspecific findings. 
The HCC may present as a "cold" defect on a sulfur-colloid study or may 
demonstrate uptake of radiopharmaceutical if the mass produces bile. Gallium 
uptake is seen in 90% of HCCs. 
Computed Tomography 
Cross-sectional imaging with CT and MRI is used most commonly to detect 
HCC. Sensitivity of good quality dual- or triple-phase CT for the detection of 
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patients with tumors is 60-70%. CT appearance of HCC varies depending on 
tumor size and the imaging phase. The most common attenuation pattern is iso-
hyper-isoattenuation on pre-, arterial, and venous phases, respectively. 
However, this pattern is shared by other hepatocellular nodules, including 
regenerative and dysplastic nodules. Unenhanced CT typically reveals an iso-
hypodense mass.33 
MRI 
HCC appearance varies on MRI depending on multiple factors, such as 
hemorrhage, degree of fibrosis, histologic pattern, degree of necrosis, and the 
amount of fatty change. HCC on T1-weighted images may be isointense, 
hypointense, or hyperintense relative to the liver. On T2-weighted images, HCC 
usually is hyperintense. Pre- and postcontrast MRI has a 70-85% chance of 
detecting a solitary mass of HCC. MRI can help differentiate cirrhotic nodules 
from HCC. Gadolinium-enhanced MRI typically demonstrates that HCCs 
densely enhance, usually in the arterial phase and particularly if they are 
small.45  
PET 
Positron emission tomography with fluorodeoxyglucose (FDG PET) is 
primarily useful in assessing the degree of differentiation and in staging 
moderately and poorly differentiated tumors than in primary lesion detection. 
Sensitivities of FDG PET for the detection of HCC range from 50-70%. This 
limited sensitivity is due to the low level of FDG uptake in well-differentiated 
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tumors. However, FDG PET may be superior to CT in detecting extrahepatic 
spread.  
Angiography 
Angiography for diagnosis of HCC has been replaced largely by cross-sectional 
imaging. Normal vasculature typically is displaced by a large mass. HCC is 
characteristically hypervascular with bizarre neovascularity and arteriovenous 
shunting. An enlarged hepatic artery may be present. Look for vascular 
invasion (portal veins, hepatic veins).45 
Treatment options 
Available treatment options depend on the size, number, and location of 
tumors; presence or absence of cirrhosis; operative risk based on extent of 
cirrhosis and comorbid diseases; overall performance status; patency of portal 
vein; and presence of metastatic disease. Surgical resection and liver 
transplantation are the only chances of cure but have limited applicability. The 
main prognostic factors for resectability are tumor size and liver function. 
Other local therapies are chemoembolization, ethanol ablation, radiofrequency 
ablation, cryoablation, and radiotherapy. Systemic treatment with 
chemotherapy may be employed.  
METASTASES 
Background: The liver provides a fertile soil in which metastases can establish, 
not only because of its rich, dual blood supply but also because of humoral 
factors that promote cell growth. (The blood supply of the liver is exceeded only 
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by that of the lung, in terms of blood flow per minute.) The fenestrations in the 
sinusoidal endothelium allow a foothold into the space of Disse for tumor 
emboli arriving via the blood stream.33  
The liver is the second most commonly involved organ by metastatic 
disease, after the lymph nodes. In Europe and the United States, a focal liver 
lesion is more likely to represent a metastatic deposit than a primary 
malignancy. The liver may be the site of metastases from virtually any primary 
malignant neoplasm, but the most common primary sites are the colon, 
stomach, pancreas, breast, and lung. Most liver metastases are multiple, 
involving both lobes in 77% patients, and only 10% are solitary.  
Pathologic-anatomic characteristics of metastases  
The pathologic anatomy of metastases resembles that of the primary tumor. 
Metastases often show the same degree of vascularity as that of the primary 
tumor. Most metastases are hypovascular, but some primaries 
characteristically have hypervascular metastases. These include metastases 
from carcinoids; leiomyosarcomas; neuroendocrine tumors; renal carcinomas; 
thyroid carcinomas; choriocarcinomas.33  
Blood flow is said to increase relative to the normal parenchyma in all 
metastases, even in hypovascular tumors. Large metastases tend to displace the 
surrounding vessels, and they may compress or occlude the portal venous 
branches. However, neovascularity, vascular encasement, and arteriovenous 
shunting are rare. Large metastases often outgrow their blood supply, causing 
hypoxia and necrosis at the center of the lesion. The patterns of blood supply of 
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liver metastases are of considerable clinical importance because of a number of 
diagnostic and therapeutic approaches depend on the degree of neovascularity, 
source and type of blood supply.  
Incidence and Distribution: Depending on the site of the primary tumor 30-
70% of patients dying of cancer have liver metastases.  
Mortality/Morbidity: A large number of local or regional treatments are now 
available. These include hepatic resection and several minimally invasive 
techniques. These treatments have been successful, particularly in the 
treatment of colorectal cancers for which hepatic resection can offer the 
potential for cure.45 Studies have shown a 20-40% 5-year survival rate after 
hepatic resection in selected patients. In patients with more-extensive disease, 
chemotherapy is now a feasible option; it may produce a response in 20% of 
patients. Hepatic involvement of metastatic tumor and the duration of survival 
appear to be inversely related. Most patients with liver metastases die with 
metastases rather than from metastases. 
Race: Liver metastases have no known racial predilection.  
Sex: The male-to-female ratio is 3:2 for colon carcinoma. The male-to-female 
ratio is 1:1 for pancreatic cancer, gastric cancer, and lung cancer. 
Age: Metastases from primary sites in the eye, colon, stomach, pancreas, 
breast, or lung affect adults, usually those in the 50- to 70-year age group.  
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Clinical Presentation: Approximately 50% of patients who die with metastatic 
carcinoma of the liver have some hepatic signs or symptoms. Hepatomegaly 
(31%) is the most common finding, followed by ascites (18%), jaundice 
(14.5%), and varices (1%). Liver function tests are notoriously unreliable for 
detecting metastases; they are normal in 25 to 50% of patients with metastases 
and can be abnormal in any number of conditions, such as parenchymal tumor 
replacement, tumor obstructing the intrapheatic or extrahepatic bile ducts, or 
chemotherapy hepatotoxicity.  
Imaging techniques: 
Plain radiograph  
A plain abdominal radiograph has a limited role in the investigation of liver 
metastases and the serial follow-up of liver metastases. Calcification is a more 
specific sign, seen in 2-3% of lesions, but it is insensitive. Common calcified 
metastases are from mucinous adenocarcinoma from stomach, pancreas, colon 
and rectum, ovarian serous lesions, leiomyosarcoma, carcinoid and medullary 
carcinoma of thyroid. 
Ultrasound and Doppler 
Ultrasound has a diagnostic sensitivity of greater than 90% in the detection of 
metastases. In the absence of complications, such as hemorrhage, infection or 
necrosis, focal metastatic liver disease presents with six basic sonographic 
patterns: hyperechoic, bulls-eye or target, hypoechoic, cystic, calcified and 
diffuse. In Doppler most of the lesions are hypovascular, some lesions may show 
intralesional flow which may be pulsatile or continuous flow with intralesional 
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peak systolic velocity less than 40 cm/s. The common hepatic artery flow has 
increased because metastases are supplied by hepatic artery.5  
Computed Tomography 
Metastases may appear in a multitude of ways on CT scans. The majority of 
liver metastases are hypovascular (hypoattenuating) compared with 
surrounding parenchyma; therefore, on nonenhanced CT scans, most lesions 
appear either hypoattenuating or isoattenuating relative to the surrounding 
parenchyma. Hypovascular lesions are routinely detected by using contrast-
enhanced techniques. The accuracy of the technique depends on the timing of 
the acquisition relative to the administration of contrast material. The optimal 
scanning time is in the portal venous phase (approximately 60 s). When 
vascular metastases are suspected, a nonenhanced scan is recommended. The 
most sensitive technique for detecting liver metastases is CT arteriography 
(CTA) and CT arterioportography (CTAP). 
MRI  
As with CT and US, liver metastases have a variety of appearances on MRI. 
Most liver tumors benign or malignant appear as hypointense lesions on T1-
weighted images and hyperintense lesions on T2-weighted images. Morphologic 
characteristics on T2-weighted images that suggest metastatic liver disease 
include the following: heterogeneous signal intensity with irregular and 
indistinct outer margins, and a smooth or irregular central area of high signal 
intensity with a surrounding ring of signal intensity lower than that of the 
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central focus but higher than that of the adjacent normal liver. Intravenous 
contrast agents improve the detection of liver mass lesions. 
Nuclear Medicine 
Metastases typically present as focal defects on both sulfur colloied and 
hepatobiliary scintiscans. They are the most common cause of focal cold liver 
lesions. PET using F-18 fluorodeoxy glucose (18-FDG) is a sensitive tool for the 
detection of liver metastases from colorectal primaries.  
Angiography 
Angiography is no longer used to diagnose liver metastases but is performed to 
provide a vascular road map for the surgeon and to guide intra-arterial 
therapy.  
HEMANGIOMA 
Hemangioma is the most common benign tumor affecting the liver. Hepatic 
hemangiomas are mesenchymal in origin and usually are solitary. Some 
authorities consider them to be benign congenital hamartomas. Hemangiomas 
are composed of masses of blood vessels that are atypical or irregular in 
arrangement and size. Etiology remains unknown.33  
Pathophysiology 
Although no definite familial or genetic mode of inheritance has been 
described, Moser et al reported a large family of Italian origin in which 3 
female patients in 3 successive generations had large symptomatic hepatic 
hemangiomas. The authors postulated that restriction of the disease to the 
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female sex could be explained by sex-dependent differences in penetrance, the 
expression of a presumed liver-hemangioma gene, or the production of 
proliferative factors, such as female sex hormones.33  
Frequency: The reported incidence rate of hepatic hemangiomas is 
approximately 2%. The prevalence rate at necropsy is as high as 7.4%. The 
widespread use of noninvasive abdominal imaging modalities has led to 
increased detection of asymptomatic lesions in vivo.45  
Sex: Women, especially with a history of multiparity, are affected more often 
than men. The female-to-male ratio is 4-6:1.  
Age: Hepatic hemangiomas can occur at all ages. Most hepatic hemangiomas 
are diagnosed in individuals aged 30-50 years. Female patients often present at 
a younger age and with larger tumors.  
Clinical Features 
Cavernous hemangiomas of the liver usually are small and asymptomatic. They 
most often are discovered when the liver is imaged for another reason or when 
the liver is examined at laparotomy or autopsy. Hemangiomas are usually 
solitary. Sizes range from 2mm to more than 20 cm. Larger and multiple 
lesions may produce symptoms. Right upper quadrant pain or fullness is the 
most common complaint. The only findings upon physical examination are, 
infrequently, an enlarged liver or the presence of an arterial bruit over the 
right upper quadrant.  
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Imaging Techniques 
Ultrasound  
This is the most commonly employed initial diagnostic tool. It is widely 
available and inexpensive. Hepatic hemangiomas usually are echogenic, but 
their sonographic appearance is variable and nonspecific. Addition of color 
Doppler to routine US provides qualitative and quantitative data and increases 
the sensitivity and specificity of the test. In Doppler hemangiomas will show 
minimal continuous or no flow with common hepatic artery showing normal 
flow. The intralesional peak systolic velocity will be less than 40cm/s.37  Serial 
US examinations can be used to monitor any increase in size of the 
hemangioma over time. Recent work has studied the use of microbubble-
enhanced US. Lesions show peripheral puddles and pools of enhancement that 
expand in a centripetal pattern during the portal venous phase of enhancement. 
With delayed imaging, the lesion may completely “fill in.” However, complete 
enhancement might not occur in large lesions where central thrombosis or 
scarring may be present. In one recent study, the addition of a contrast agent to 
routine US improved sensitivity from 78% to 100% and specificity from 23% 
to 92%. In general, the US finding of a suspected hemangioma should be 
diagnostically integrated with CT scan or MRI to assure a correct diagnosis.34 
Computed Tomography 
Dynamic contrast-enhanced CT scanning is preferred to routine CT scanning. 
When requesting a CT scan to investigate a liver mass, the physician should 
inform the radiologist about the need for nonenhanced, arterial, portal venous 
and delayed imaging (the so-called triple phase CT with delayed imaging). 
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First, the liver is imaged by CT before the administration of intravenous 
contrast. The next series of images is obtained about 30 seconds after the 
injection of contrast, at the time that contrast is entering the liver via the 
hepatic artery. Portal venous imaging occurs 60 seconds later, as contrast is 
returning to the liver from the mesenteric veins via the portal vein. Finally, 
delayed images are obtained several minutes later. Hepatic hemangiomas are 
typically hypodense on precontrast imaging. In arterial phase, there may be 
enhancement of the peripheral portions of the lesion. There may be ring 
enhancement or globular enhancement. The center of the lesion typically 
remains hypodense. In portal venous phase and in delayed images, contrast 
enhancement progresses centripetally. The center of the lesion may only 
become hyperdense in delayed images.33 
Magnetic resonance imaging 
MRI is highly sensitive and specific in the diagnosis of hepatic hemangioma. 
Typically, hemangiomas have low signal intensity on T1-weighted images and 
high signal intensity on T2-weighted images. When gadolinium is employed as 
an intravenous contrast agent, hemangiomas enhance in a fashion similar to 
that seen on dynamic CT.45  
Nuclear medicine 
Tc-99m pertechnetate-labeled RBC pool studies have been used for many years 
to help diagnose hepatic hemangiomas. For lesions that are greater than 2 cm 
in diameter, the sensitivity of the test has been reported at 82%. The specificity 
is up to 100%. SPECT with 99mTc-labeled RBCs improves the sensitivity of the 
test for detecting small hemangiomas.33 
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Following are various studies to differentiate HCC, metastases and 
hemangioma more than 2 cm using colour Doppler sonography.  
Numata K, Tanaka K, Kiba T, Morimoto M et al37 evaluated hepatic 
tumor index on colour Doppler sonography for differentiating large hepatic 
tumors. 80 patients with 108 hepatic lesions more than 2 cm are evaluated. A 
peak systoloic velocity of 40 cm/s or greater suggested a malignant hepatic 
tumor rather than a hemangioma, with a sensitivity of 67%, a specificity of 
91% and an accuracy of 71%. A hepatic tumor index equal to or greater than 1 
was associated with 76% sensitivity, 92% specificity and 82% accuracy in 
distinguishing hepatocellular carcinomas and metastases. In lesions with a 
tumoral peak systolic velocity of 40 cm/s or greater, a hepatic tumor index 
equal to greater than 1 was associated with 91% sensitivity, 83% specificity and 
89% accuracy in distinguishing hepatocellular carcinomas from hepatic 
metastases.   
Tanaka S, Kitamura T, Fujitha M et al51 made a study on differential 
diagnosis of liver tumors on the basis of the pattern of blood flow within and 
around tumors on colour Doppler flow images. 35 patients with liver mass 
lesions are analysed: 20 patients had hepatocellular carcinoma, six had 
hemangiomas four had metastatic lesions, one had cholangiocellular carcinoma, 
one had focal fatty liver and three had liver cysts. A basket pattern (a fine 
blood-flow network surrounding the tumor nodule) was observed in 15 (75%) 
of the 20 HCCs. In patients with multiple hepatic metastases a detour pattern 
(a dilated portal vein meandering around the tumor nodules) was observed. In 
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three of six hemangiomas, a spot pattern (colour stained dots or patches in the 
central region of the tumor). Their experience suggests that hepatocellular 
carcinomas have a characteristic appearance on colour Doppler flow images.   
Gonzalez M, Cervera J, Garcia JH et al15 evaluated the usefulness of 
colour Doppler and duplex sonography in the characterization of 106 solid liver 
lesions. With colour Doppler, the aspect and distribution of tumoral vessels and 
the pulsed Doppler parameters are considered only for those showing the 
highest systolic peak velocity values. Intra tumoral colour and pulsed Doppler 
signals were obtained in 81% of malignant tumors (p<0.0001) but only in 18% 
of benign tumors. Ninety percent of the lesions with arterial intratumoral and 
peritumoral signals were malignant, whereas 4% were benign (p<0.0001). Only 
11% of  malignant lesions had intratumoral venous signal vis-à-vis 70% benign. 
The type of signal (arterial or venous) and its distribution detected by colour 
and pulsed Doppler is more helpful than the assessment of the spectral 
quantitative parameters obtained by pulsed Doppler. The presence of 
intratumoral venous flow remarkably suggests benignancy. The presence of 
both intra and peritumoral arterial flow in the same lesion strongly suggests 
malignancy.  
Lin ZY, Wang LY, Wang JH, Lu SN et al31 assessed the clinical 
utility of colour Doppler sonography in the differentiation of hepatocellular 
carcinoma from metastases and hemangioma. They investigated 72 
hepatocellular carcinomas (80 lesions), 30 metastases (82 lesions) and 39 
hemangiomas (54 lesions). Overlaps of colour pattern were found among 
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hepatocellular carcinoma, metastases and hemangioma. Pulsatile waves from 
lesions with the basket vessels within the tumor or spot patterns or lesions less 
than 3 cm with detectable signals did not favour the diagnosis of hemangioma. 
Colour Doppler sonography can aid in the differentiation of HCCs from 
hemangioma but may be unreliable in the differentiation of HCCs from 
hypervascular metastases.  
Yasuhara K, Kimura K, Ohto M, Matsutani S et al59 studied blood 
flow detection using Doppler ultrasound in primary HCCs as well as in 
metastatic liver cancer and hemangioma. The pulsatile wave which was 
detected from HCC (35 out of 48 lesions) and metastatic liver lesions (in all 
seven with positive signals) and the continuous wave, which was seen from 
HCC (41 out of 48) and hemangioma (in all four with signals). In six patients 
who underwent transarterial embolization, the pulsatile wave detected before 
therapy disappeared immediately thereafter and it is possible that this type of 
wave originates from tumor vessels. Small hypoechoic mass lesions appearing 
in liver cirrhosis such signals were demonstrated, even in 8 of 10 small 
hepatocellular carcinoma less than 2 cm in diameter, whilst they are not 
detected from nine regenerative nodules related to cirrhotic change. Doppler 
ultrasound method may be a useful in detecting blood flow within liver tumors 
and may offer the possibility of differential diagnosis of small tumors.  
Oguma M, Kawano M, Monma T et al40 evaluated the diagnostic 
significance of blood flow pattern and velocity in hepatic tumors detected by 
colour Doppler ultrasonography. 57 patients with HCC and 12 patients with 
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hemangioma were studied. The detection rate of blood flow in HCC was 
significantly higher than in hemangioma . Pulsatile flow was detected in 43 of 
57 patients with HCC. Average maximum velocity of pulsatile flow was over 40 
cm/s. Analysis of blood flow after treatment provided useful on the effect of 
treatment. Analysis of blood flow in hepatic tumors on US with colour Doppler 
system may provide useful information on differential diagnosis between HCC 
and hemangioma, the assessment of the therapeutic effect of TAE or PEI, 
whether additional treatment is required or not, and when it should be done if 
required.   
Wang WP, Xu ZZ, Shen SC et al54 studied colour Doppler and pulsed 
Doppler in 56 patients with 71 solid hepatic lesions smaller than 3 cm in 
diameter. The detecting rates of arterial signals in small hepatocellular 
carcinomas group, hemangiomas group and otheres group were 86.9%, 37% 
and 33% respectively. Whereas, the average value of resistance index (RI) in 
small HCC group was very higher than (more than 0.5) that in other groups. 
The specificity of 96% and accuracy of 90% for the diagnosis of HCC and is 
superior to conventional USG. 
Tang J et al52 examined 40 cases of primary liver cancer with colour 
Doppler flow imaging and duplex Doppler. In 20 cases, there was arterial flow 
in the tumor. In 17 cases, there was arterial and portal venous flow in the 
tumor. In 22 cases, there was arterial flow entering the tumor from its 
surroundings. In 28 cases, the right or left hepatic artery was dilated. They 
compared the results of DSA with the Doppler ultrasound in 28 cases and 
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found the difference was not significant (p>0.05). They concluded that Doppler 
ultrasonography is the method of choice in the diagnosis of primary liver 
cancer.    
Shrivastava DN, Mahajan A, Berry M, Sharma MP et al49 evaluated 
54 focal liver lesions with colour Doppler flow imaging (CDFI) to differentiate 
various types of lesions based on the flow pattern in terms of peritumoral and 
intratumoral blood flow. Marked intratumoral flow on CDFI was seen in 
12.5% of primary hepatic malignancies and in infantile hemangioendothelioma, 
while a moderate flow pattern was seen in 56.2% of HCC and 18.7% of 
metastases; and 16.7% of hemangiomas. No intratumoral flow was seen in 
100% of inflammatory lesions; 83.3% hemangiomas; 62.5% of metastases; and 
only one HCC (5.6%). Finally they concluded that CDFI when used along with 
other morphological imaging features, can assist in diagnosis or in narrowing 
the list of different diagnoses in a particular clinical situation.  
Gaiani S, Casali A, Serra C, Piscaglia F et al14 aimed to investigate 
the value and limitation of the different Doppler ultrasound modalities 
(spectral analysis, colour and power Doppler imaging) in the differential 
diagnosis of small liver tumors to identify the optimal diagnostic approach with 
the presently available Doppler technology. Presence and distribution of colour 
and power Doppler signals, Doppler peak frequency, resistive index and 
systolic accelereation time were examined in 133 liver nodules (< or = 4 cm). By 
discriminant analysis, peak frequency (cut-off 1320 Hz) differentiates small 
hepatocellular carcinoma (< or =2 cm) from macroregenerative nodules and 
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hemangiomas (accuracy 92.6%); resistive index (cut-off 0.65) differentiates 
malignancies from benign lesions (accuracy 83.8%); and systolic acceleration 
time (cut-off 105 ms) differentiates hepatocellular carcinoma from metastases 
(accuracy 80.9%). 
Morimoto Y, Kubo S, Shuto T, Tanaka et al35 studied the 
hemodynamics of intrahepatic tumors using power Doppler sonography. They 
used conventional B-mode ultrasonography, power Doppler ultrasonography 
and dynamic computed tomography to examine 71 hepatocellular carcinomas 
(</= 3 cm) before liver resection. Nodules with afferent pulsatile waves was 
higher in moderately or poorly differentiated hepatocellular carcinomas. 
Afferent continuous waves were detectable only in well-differentiated HCC. 
They concluded that Power Doppler can usually distinguish moderately or 
poorly differentiated from well-differentiated HCCs, which is useful in 
planning treatment and predicting outcome.  
Kamalov IR, Sandrikov VA, Gautier SV, Tsirulnikova OM, 
Skipenko OG et al19 developed a standard protocol of colour velocity and 
spectral Doppler ultrasound of liver tumor vascularization and to estimate the 
value of this method in differentiation of liver tumors. 68 patients with 128 
primary and secondary liver tumors were observed. Qualitative features (vessel 
presence, vessel location and waveform of tumor vessel blood flow) and 
quantitative features (vessel quantity per cm2,   vessel diameter, maximum 
velocity (Vmax), and resistance index (RI) of tumor artery and Vmax of tumor 
vein) are assessed. They concluded that tumor vascularization was found more 
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frequently in hepatocellular carcinoma than cavernous hemangioma or 
metastatic liver lesion (p<0.01).  
Ignee A, Weiper D, Schuessler G, Teuber G, Faust D et al17 
investigated 100 consecutive patients with histologically proven hepatocellular 
carcinoma in order to evaluate sonographic characteristics in unselected 
patients and compared native and contrast enhanced techniques. The 
ultrasound appearance with conventional B-mode of hepatocellular carcinoma 
was hypoechoic in 48% of the cases, isoechoic in 9% cases, hyperechoic in 19% 
and in 25% a mixture between hyper and hypoechoic appearance was found 
compared to surrounding liver tissue. Contrast enhanced power Doppler 
techniques with SHU 508A changed the pattern of tumor vascularity in 27% of 
patients into hypervascular, mainly in small lesions. They concluded that the 
use of ultrasound contrast media should be considered to achieve 
characterization of liver nodules in cirrhotic livers because they can improve 
the evaluation of tumor vascularity. Hypovascular HCC are found in about 
10% even after the administration of contrast agent.  
Strunk H, Stuckmann G, Frohlich E et al50 evaluated the 
characterization of liver lesions using power Doppler sonography before and 
after intravenous injection of the ultrasound contrast Levovist. They studied 39 
patients with 41 liver lesions (10 hemangiomas, 2 focal nodular hyperplasias, 2 
focal fatty infiltrations, 1 echinococcal lesion, 11 HCCs, 14 metastases and one 
cholangiocarcinoma). Power Doppler images before and after intravenous 
injection of the ultrasound contrast agent Levovist were analysed. Distribution 
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of flow (peripheral, central and diffuse) and amount (none, minimal, moderate 
and strong) of flow pattern in each sonographic examination. Histological 
verification was obtained in all liver lesions, except in hemangiomas, where MR 
imaging and in one FNH where scintigraphy was regarded as sufficient proof. 
On the whole,  power Doppler sonography ws superior to unenhanced power 
Doppler sonography in 20 liver lesions and equal in 7. They concluded that 
intratumoral signal favour a malignant tumor. The absence of flow signals is a 
frequent finding in benign lesions but does not rule out malignancy.  
Imamura M, Shiratori Y, Shiina S, Sato S et al18 done this study to 
characterize the factors contributing to the power Doppler signals of HCC. 
Correlation of Doppler signals of HCC in 114 patients with 178 HCC nodules 
was analyzed in relation to the findings of CT and angiography, tumor 
characteristics (size, echo pattern and histological differentiation of tumor), 
viral markers and severity of liver disease. The sensitivity of power Doppler US 
was superior to that of CT and angiography (each p<0.05). The detection rate 
of power doppler signal was significantly higher in tumors with diameter > or 
=2 cm (vs <2 cm in diameter), and with low/mixed echo pattern (vs high echo 
appearance), and with moderately / poorly differentiated HCC (vs well 
differentiated HCC). They concluded that tumor characteristics play an 
important role in power Doppler signals an that these could be assessed by the 
presence or absence of power Doppler signals.   
Numata K, Tanaka K, Mitsui K, Inoue S et al39 studied benign and 
malignant hepatic tumors with colour Doppler sonography and arteriography 
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in order to correlate colour Doppler flow characteristics with tumor 
hemodynamics (vascularity, arteriovenous shunting, and portal vein 
involvement) shown by arteriography. They also evaluated the usefulness of 
colour Doppler flow characteristics in discriminating between tumor types. 
Colour Doppler sonography and arteriography was performed in 58 patients 
with 72 hepatic lesions larger than 2.0 cm in diameter. Differences in pulsatile 
flow (peritumoral or intratumoral) and the highest systolic peak flow velocities 
reached were evaluated on colour Doppler sonograms and compared with 
arteriography. The mean peak systolic flow velocity seen in hepatocellular 
carcinomas (0.52 cm/s) significantly exceeded the velocity seen in hemangiomas 
(0.16 m/s), but not the velocity in other malignant hepatic tumors (0.51 m/s). 
Finally they concluded that colour Doppler sonography was useful for 
evaluating hepatic tumor hemodynamics as seen at arteriography, and peak 
systolic velocity may be useful in differentiating malignant hepatic tumors from 
hemangiomas.     
Wang YF, Zhang QP et al55 used duplex Doppler ultrasound and 
colour Doppler flow imaging to study the characteristics of blood supply in 
neoplasms in 51 cases of 60 liver tumors, and compared with results of surgery, 
pathological examination and hepatic arterial angiography. The result showed 
that: 1)Doppler flow signals could be detected in all hepatic carcinomas, and in 
10 cases of 18 hemangiomas, significant difference was observed (p<0.001); 2) 
Doppler blood flow spectra showed pulsatile pattern in 41 of 42 hepatic 
arcinomas, and in 6 of 10 hemangiomas (p<0.01); and 3) the peak systolic flow 
velocity was obviously lower in hemangioma group than in hepatic carcinoma 
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group (20.34 +/- 23.93 vs 64.74 +/- 30.18 cm, p<0.001). They concluded that 
colour flow characteristics of hemangiomas and HCCs are different and the 
blood supply of hepatic carcinomas mainly comes from hepatic arterial system, 
and is of value in duplex Doppler ultrasound and CDFI.     
Kudo M, Tochio H, Zhou P et al24 evaluated Doppler spectral analysis 
using colour Doppler sonography in a total of 133 patients with 135 hepatic 
lesions, including 88 HCCs, 30 metastatic hepatic cancers, 15 hemangiomas and 
2 focal nodular hyperplasias. Maximum velocity (Vmax)  of HCCs was 
significantly higher than hemangiomas. HCC showed wide spectrum in terms 
of Vmax and PI. Specificity of Vmax more than 60 cm/s and PI more than 2.0 
for the diagnosis of HCC were 92 and 94% respectively. 87% of hemangiomas 
showed relatively lower Vmax (<30 cm/s) and low PI (<1.0 cm/s). When taking 
account of both parameters, Vmax and PI, diagnostic efficacy for hemangioma 
and HCC are greatly improved (sensitivity, specificity, accuracy, positive 
predictive value and negative predictive value of 80, 86, 85, 41 and 97% 
respectively, in hemangioma, and 38, 85, 54, 83 and 58%, respectively, in 
HCC). They concluded that in addition to the information obtained by Vmax, 
simultaneous measurement of PI adds valuable information useful in the 
noninvasive differentiation among hepatic tumors by Doppler spectral analysis 
at colour Doppler US.  
Lee MG, Auh YH, Cho KS, Chung YH et al28 evaluated the role of 
colour Doppler in differentiating HCCs from metastases and hemangiomas by 
the amount of tumoral colour signals. Intratumoral and peritumoral colour 
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signals were analyzed by a three-step grading system (grade 1 to 3) in 51 
patients (32 HCCs, seven metastases, and 12 hemangiomas). Correlation of 
grading scores for intratumoral and peritumoral colour signals was evaluated 
with the size of the tumors as well. HCCs demonstrated a higher grade of 
intratumoral colour signals than did metastases or hemangiomas in all (p<0.05) 
and biopsy proved lesions (p=0.0084). There was no significant difference in the 
degree of peritumoral colour signals in all (p>0.05) or 17 biopsy-proved HCCs 
(p=0.2078) from the other tumor groups. Grade of both intratumoral and 
peritumoral colour signals was not related with the tumor size in all groups 
(p>0.05). They concluded that colour Doppler imaging provided a valuable role 
in the diagnosis of HCCs based on the qualitative analysis of the intratumoral 
colour signals.   
Liang P, Cao B, Wang Y, Yu X, Yu D et al30 conducted a study to 
evaluate the effectiveness of sonography, especially colour Doppler sonography, 
in the differential diagnosis of cystic hepatic lesions. 92 pathologically proven 
hepatic cystic lesions (20 cystic malignancies, 24 abscesses and 48 simple cysts) 
were evaluated with gray-scale and colour Doppler sonography. On gray scale 
sonography, the simple cysts were easily distinguished from cystic malignancies 
and abscesses. While no significant differences were found between hepatic 
cystic malignancies and hepatic abscesses on gray scale US. The sensitivity and 
specificity of colour Doppler sonography in differentiating cystic malignancies 
from abscesses and simple cysts were 85% and 96%, respectively. They 
concluded that presence of colour signals in the solid portion of the cystic 
 54
lesions carries a high diagnostic value in differentiating hepatic cystic 
malignancies from abscesses and simple cysts.   
Kumada T, Nakno S, Toyoda H, Hayashi K, Kiriyama S, Sone Y et 
al25 evaluated the usefulness of Doppler ultrasonography (DUS) for the analysis 
of tumor hemodynamics in small HCC. They compared DUS findings with 
CTAP and CTA in the evaluation of the intratumoral hemodynamics and with 
pathologic findings in 45 small HCC nodules (< or =3.0 cm in diameter) of 43 
patients. DUS flow pattern of each nodule categorized into three types: afferent 
continuous flow (Type 1), afferent pulsatile flow with afferent continuous flow 
(Type 2) and afferent pulsatile flow without afferent continuous flow (Type 3). 
Intratumoral blood supply was determined by Angio-CT, and pathologic 
findings were evaluated on resected or biopsied specimen. DUS findings well 
represented blood supply of HCC evaluated by Angio-CT. In addition, all Type 
1 and 2 nodules were well-differentiated HCC, and all Type 3 nodules were 
moderately or poorly differentiated HCC. They concluded that DUS is a non-
invasive imaging method and can be used for the evaluation of the stage of 
malignancy of small HCC.  
Shirato K, Numata K, Mitsui K, Kitamura T, Morita K et al48 
evaluated 86 patients with 92 HCCs (2.0 cm or greater in diameter) who 
underwent colour Doppler sonography before and after transcatheter arterial 
embolization and after subsequent percutaneous ethanol injection for 1) 
identification of pulsatile flow in the reisudal tumor area after TAE, 2) 
evaluation of therapeutic effectiveness of combined TAE and PEI, and 3) 
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detection of recurrence during follow-up evaluation. Before and 2 weeks after 
TAE, colour Doppler sonography revealed pulsatile flow in 76 and 43 lesions, 
respectively. During follow-up study colour Doppler sonography revealed 
pulsatile flow in 76.3% (local) and 63.2% (new). They concluded that colour 
Doppler sonography was useful for complying with our three objectives, 
especially for detecting local recurrence during follow-up evaluation. 
Numata K, Tanaka K, Kiba T, Saito S, Kirikoshi H et al38 assessed a 
possible correlation between the hepatic tumor index (as the ratio of the 
tumoral PSV to the PSV of the right or left hepatic artery) and grade of tumor 
vessel in large HCCs. Colour Doppler findings were evaluated and compared 
with selective hepatic arteriographic findings in 78 patients with 93 HCCs 
larger than 2.0 cm diameter. Pulsatile colour flow images were obtained in 78 
of 93 lesions. The hepatic tumor index was equal to or greater than 1.0 in 57 of 
78 lesions. These lesions were revealed arteriographically to have distinct 
tumor vessels and or arteriovenous shunting. When this index was 1.0 or 
greater,  they calculated 90% accuracy in distinguishing HCCs with distinct 
tumor vessels from those without distinct tumor vessels. They concluded that 
hepatic tumor index correlated with the grade of tumor vessels and the 
presence of arteriovenous shunting.    
Arai K et al2 assessed the value of colour duplex Doppler sonography in 
evaluating tumor vascularity in 82 hepatic tumors (61 HCCs, 11 metastatic 
cancers, 8 adenomatous hyperplasia, one focal nodular hyperplasia and one 
cholangiocellular carcinoma). 28 (74%) of 38 tumors with signals within them 
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had definite tumor vessels on angiography and continuous blood flow within 
the tumors showed as association with dilated tumor vessels. 31% of tumors 
less than or equal to 3 cm showed signals within them in contrast to 78% of 
tumors greater than 3 cm. They concluded that Doppler sonography is 
somewhat useful in evaluating tumor vascularity, but less so in small tumors.    
Shimamoto K, Sakuma S, Ishigaki T, Ishiguchi T et al47 evaluated 15 
patients of HCC with colour Doppler ultrasound, magnetic resonance imaging, 
dynamic computed tomography and angiography. Doppler signals ranging 
from 0.22 to 3.48 KHz could be obtained from within the tumor in 14 of 15 
patients. The resistive index was 0.38-0.77. Colour Doppler signals were 
visualized in 9 of 15 patients with a Doppler shift greater than 0.7 KHz. The 
Doppler signals and the RI of tumor vessels became lower as the vessels 
progressed into the center of the lesion. The appearance of tumor vessels 
recognized on MR images obtained with gradient-recalled acquisition in the 
steady state (GRASS) in 11 of 15 lesions was compared with that on CT scans 
and angiograms. Tumors that were hyperintense on GRASS images obtained 
with flip angle of 15 degrees transmitted Doppler signals of considerably higher 
amplitude compared with the isointense lesions. They concluded both colour 
Doppler US and MR imaging provided useful information for characterizing 
intratumoral blood flow. 
Dock W, Grabenwoger F, Metz V, Eibenberger K et al10 examined 
123 patients with benign and malignant neoplasms (breast cancer, n=44; liver 
neoplasms, n=43; and tumors affecting other organs, n=36) to establish general 
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criteria for evaluation of neoplastic lesions by means of duplex sonography.  
The frequency shifts determined by means of different Doppler requencies 
(2.31 or 3.75 MHZ) were converted in flow velocities. Only the highest systolic 
peak flow velocity obtained from a lesion was used for statistical evaluation. 
Receiver operating characteristic curves showed that a flow velocity of 40 cm/s 
is the optimal threshold value with which benign from malignant tumors can be 
differentiated. The data indicated that only positive findings are potentially 
reliable. They concluded that negative results of sonography should not be used 
to diagnose the presence of a benign lesion.     
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MATERIALS AND METHODS 
A prospective study of 63 patients with 88 liver lesions detected on gray 
scale ultrasound referred from the Departments of Gastroenterology and 
Surgery was done in Barnard Institute of Radiology, Madras Medical College 
between February 2004 to December 2005. They were subjected to ultrasound, 
colour Doppler USG and CECT. The histopathological diagnosis was taken as 
the gold standard for confirmation of Hepatocellular carcinoma and metastases 
and  triphasic CECT was taken as the gold standard for confirmation of 
hemangioma. Only adult patients are included in the study. There were no 
limitations to study with respect to sex.  
CASES: 
INCLUSION CRITERIA: 
All adult patients with liver tumor on gray scale ultrasound more than 2 cm in 
diameter 
EXCLUSION CRITERIA: 
1) History of surgery 
2) History of chemotherapy 
3) History of FNAC / biopsy of liver lesion 
4) Very obese patients (nonvisualization or poor colour flow 
visualization of hepatic artery due to deep location) 
5) Lesions less than 2 cm in diameter (the colour flow signals of such 
small lesions are not sufficiently distinct) 
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EQUIPMENT AND TECHNIQUE 
Gray scale and colour Doppler sonography were performed using Aloka 3500 
SSD series unit. Gray scale sonography was performed at 3.5 MHz curved 
array transducer.         
In the USG following parameters have taken for consideration.  
1)Lesion Size 
2)Shape    
3)Margins 
4)Number 
5)Location (right or left lobe, segments) 
6)Echogenicity 
7)Calcification 
8)Adjacent vessel involvement(portal vein thrombus) 
9)Bile duct dilatation 
10)Liver echoes and architecture (cirrhotic liver) 
11)Regional lymphadenopathy 
12)Ascites 
In all examinations, colour assignment was chosen so that flow toward 
the trasnsducer was red and the flow away from the transducer was blue. 
Threshold levels were set to optimize the sensitivity without having excessive 
noise, examinations were performed at various flow settings, depending on the 
flow velocities. Examinations included real time colour images of the lesion, 
followed by point spectral analysis. Velocity was calculated from multiple 
 60
peritumoral and intratumoral arteries visualized in the two dimensional 
images. Velocity measurements were obtained at peak systole and end diastole 
after correction for the angle of insonation. A Doppler angle of 0 to 60 degrees 
was used when possible to reduce errors in velocity calculations. Of the five to 
20 measurements obtained from each tumor, only the highest systolic peak flow 
velocity obtained from a tumor was used for statistical evaluation. Common 
hepatic artery flow and angle corrected PSV measurements are taken at the 
level of porta hepatis. The hepatic tumor index was calculated (defined as the 
ratio of the peak systolic velocity in the tumor to the peak systolic velocity in 
the hepatic artery).  
In Doppler, we see the following 
1)Intralesional flow pattern (pulsatile flow, continuous flow, basket pattern or 
spot pattern, central or peripheral flow) 
2)Intralesional peak systolic velocity 
3)Common hepatic artery peak systolic velocity 
4)Tumor index (intralesional PSV / common hepatic artery PSV) 
5)Portal vein involvement  
Lesions are examined with USG, Doppler confirmed by FNAC, biopsy 
and CECT.  
This study confines to ethics and was done with the consent and full 
cooperation of the patients.  
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FIG 1.NORMAL LIVER GREY SCALE AND COLOUR 
DOPPLER         
 
 
FIG 2. COMMON HEPATIC ARTERY ORIGIN        
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FIG 3. HEPATOCELLULAR CARCINOMA                                  
  
 
FIG 4. PULSATILE, HIGH VELOCITY ILFLOW>40 CM/S 
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FIG 5. HCC INTRA LESIONAL AV SHUNTING 
 
 
                      
 
FIG 6. NORMAL COMMON HEPATIC ARTERY FLOW 
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FIG 7. HCC WITH INCREASED COLOUR FLOW                     
 
 
 
FIG 8. PULSATILE HIGH VELOCITY ILFLOW 
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FIG 9. INCREASED FLOW IN CHA BUT PSV<ILPSV 
 
 
 
 
      
 
 
 
 
 
 FIG 10. LARGE HCC WITH INCREASED ILFLOW 
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FIG 11. PULSATILE ILFLOW WITH ILPSV>40 CM/S 
FIG 12. CHA PSV < INTRALESIONAL PSV 
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FIG 13. NO INTRA LESIONAL FLOW IN METASTASES 
FIG 14. MINIMAL INTRALESIONAL FLOW IN METASTASES 
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FIG 15. MINIMAL CONTINUOUS FLOW INTRALESIONAL FLOW WITH 
PSV<40 CM/S, WITH HIGHLY ELEVATED CHA FLOW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG 16. METASTASES WITH CONTINUOUS INTRA LESIONAL FLOW 
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FIG 18. MULTIPLE HYPERECHOIC METASTASES WITH NO FLOW 
 
            
FIG 17. COMMON HEPATIC ARTERY FLOW IN METASTASES 
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FIG 20. HEMANGIOMA WITH SPOT PATTERN OF MINIMAL 
CONTINUOUS INTRA LESIONAL FLOW WITH ILPSV<40 CM/S 
 
 
FIG 19. HIGHLY ELEVATED CHA FLOW IN METASTASES 
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 FIG 22. MULTIPLE HEMANGIOMAS WITH NO IL FLOW 
             
 
 
FIG 21. NORMAL FLOW PATTERN IN HEMANGIOMA IN CHA 
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FIG 23. HEMANGIOMA WITH NO COLOUR FLOW          
 
 
 
         FIG 24. COMMON HEPATIC ARTERY FLOW IN HEMANGIOMA 
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RESULTS AND ANALYSIS 
The ability of colour Doppler ultrasound to characterize HCCs, 
metastases and hemangiomas and are compared with HPE for HCCs and 
metastases and with CECT for hemangiomas. The final HP findings after 
FNAC / Biopsy were accepted as reference standards for HCCs and metastases 
and CECT was accepted as reference standard for hemangioma against which 
colour Doppler ultrasound results were compared.  
Sensitivity, specificity, correct classification, misclassification, positive 
predictive value, negative predictive value, false positive rate, false negative 
rate were calculated for colour Doppler ultrasound in differentiating HCCs, 
metastases and hemangiomas from each other.  
A test is said to be sensitive when the percentage of false negative is low. 
A test is said to be specific when the percentage of false negative is low. Positive 
and negative predictive value estimates probability of presence or absence of a 
particular lesion. False positive means disease is present in a test when in fact it 
is not. False negative means failure of a test to detect a disease when it is 
present.  
For diagnostic tests that produce results on continuous scale of 
measurement, the performance of a test can be represented graphically by a 
receiver operating characteristic curve (ROC). The area under the ROC curve 
serves as an overall measure of test performance, with an area of 1 indicating a 
perfect test and an area of 0.5 indicating a test that is unable to distinguish 
persons with and without the disease of interest. The respective areas under the 
ROC curves for 2 diagnostic tests for a particular disease can be used to 
identify the test that will provide the greater diagnostic value. 
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AGE DISTRIBUTION 
 
                                         TYPE 
         HCC        Metastases      Hemangioma           Total 
    Age  Count    %   Count    % Count % Count      % 
20 - 40     3    12      1    6.7     3 13.0 7    11.1 
40 - 60    18     72      7   46.7    15 65.2 40     63.5 
> 60     4     16      7   46.7      5 21.7 16     25.4 
Total    25    100     15  100.0    23 100.0 63    100.0 
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SEX DISTRIBUTION 
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                                             TYPE 
HCC Metastases Hemangioma            Total 
SEX Count   % Count     %   Count % Count % 
Male    18   72      8    53.3     10  43.5 36 57.1 
Female     7   28      7    46.7     13  56.5 27 42.9 
Total    25 100     15  100.0     23 100.0 63 100.0 
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TYPES OF LESIONS ACCORDING TO NO. PATIENTS 
 
                                             
 
 
                           
 
 
Types of lesions(No. of patients)
HCC
39%
Metastases
24%
Hemangioma
37%
 
ACCORDING TO NO. OF LESIONS 
 
                                                
 
 
                                                              
                                      
           
Types of lesions(No. of lesions)
HCC
34%
Metastases
36%
Hemangioma
30%
 
         Type No. of patients 
 HCC 
            25 
Metastases 
            15 
 Hemangioma 
             23 
Total 
             63 
        Type Frequency 
HCC       30 
Metastases       32 
Hemangioma       26 
Total       88 
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CLINICAL PRESENTATION 
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TYPE 
Clinical presentation HCC Metastases Hemangioma Total 
Asymptomatic          3         20  23 
Abdominal pain   9         4          3  16 
Constitutional symptoms   3         2     5 
Hepatomegaly   4         3     7 
Ascites   9         3    12 
Total  25        15         23   63 
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LESION LOCATION 
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Location  HCC Metastases Hemangioma Total  
Right lobe 25 24 22 71 
Left lobe 5 8 4 17 
Total 30 32 26 88 
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SIZE OF LESIONS 
 
  
 
 
 
Size of the lesion
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Type    NO Mean Median Minimum Maximum Std. Deviation 
HCC 30 6.4 6.25 3.7 10.2          1.51 
Metastases 32 3.6 3.7 2.1 6.3          1.05 
Hemangioma 26 3.3 3.1 2.2 6.4          1.01 
Total 88 4.5 4.2 2.1 10.2          1.83 
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GRAY SCALE APPEARANCE OF LESIONS 
 
Echogenicity  HCC Metastases Hemangioma Total  
Hypo echoic  6       11    17 
Iso echoic           9     9 
Hyper echoic   9         5        21  35 
Calcified           4     4 
Mixed  15        3         5  23 
Total   30        32        26   88 
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INTRALESIONAL PSV 
 
Type   No Mean Std. Deviation 
HCC 30 75.1 33.11 
Metastases 32 24.1 15.04 
Hemangioma 26 19.0 16.46 
Total 88 39.9 34.25 
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COMMON HEPATIC ARTERY PSV 
 
Type   No Mean Std. Deviation 
HCC 30 72.9 17.06 
Metastases 32 108.4 34.90 
Hemangioma 26 58.1 8.35 
Total 88 81.4 31.72 
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HEPATIC TUMOR INDEX 
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Type No lesions Mean Std. Deviation 
HCC 30 0.99 0.33 
Metastases 32 0.23 0.22 
Hemangioma 26 0.33 0.32 
Total 88 0.52 0.45 
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DIFFERENTIATION OF HCC BY COMBINING ILF, ILPSV, CHAPSV AND TI 
 
    
 
HPE 
HCC 
+ - 
Total 
 Doppler +        25        3       28 
 Doppler -         5       55       60 
     Total        30       58       88 
                              p<0.001 
 
 
 
 
 
 
 
 
 
PARAMETERS % CONFIDENCE        LIMIT 
Sensitivity 83.3 65-94% 
Specificity 94.8 86-99% 
Concordance 90.9 79-97% 
Discordance 9.1 3-21% 
Positive predictive value 89.3 72-98% 
Negative predictive value 91.7 82-98% 
False positive rate 5.2 1-14% 
False negative rate 16.7 6-35% 
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DIFFERENTIATION OF METASTASES BY COMBINING ILF, ILPSV, 
CHAPSV AND TI 
 
 
HPE 
Metastases 
+ - 
Total 
Doppler +         28         1  29 
Doppler  -          4        55 59 
Total         32        56 88 
        p<0.001 
   
 
 
 
 
 
 
 
PARAMETERS % CONFIDENCE        LIMIT 
Sensitivity 87.5 71-97% 
Specificity 98.2 91-100% 
Concordance 94.3 85-99% 
Discordance 5.7 1-15% 
Positive predictive value 96.5 82-100% 
Negative predictive value 93.2 84-98% 
False positive rate 1.8 0-9% 
False negative rate 12.5 3-29% 
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DIFFERENTIATION OF HEMANGIOMA BY COMBINING ILF, ILPSV, 
CHAPSV AND TI 
 
 
CECT 
Hemangioma 
+ - 
Total 
Doppler +         23         8  31 
Doppler -          3        54 57 
         Total         26        62 88 
   p<0.001 
 
 
 
 
 
 
 
PARAMETERS % CONFIDENCE        LIMIT 
Sensitivity 88.5 70-98% 
Specificity 87.1 76-94% 
Concordance 87.5 76-93% 
Discordance 12.5 7-24% 
Positive predictive value 74.2 55-88% 
Negative predictive value 94.7 85-99% 
False positive rate 12.9 6-24% 
False negative rate 11.5 2-30% 
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Metastases (Area under the curve = 0.929) 
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Hemangioma (Area under the curve = 0.862) 
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DISCUSSION 
Gray scale ultrasound and CDS were performed on 63 patients with 88 
lesions in the liver referred by Departments of Gasteroenterology and Surgery. 
Out of 63 patients, 25 patients had HCCs, 15 patients had metastases 
and 23 patients had hemangiomas. Out of 25 HCC patients, 72% (18) were 
male patients, 28% (7) female patients. Out of 15 patients with metastases, 
53.3% (8) were male patients, 46.7% (7) were female patients. Out of 23 
patients with hemangiomas 43.5% (10) patients were male, 56.5% (13) patients 
were female. In total 36 male patients and 27 female patients. Male to female 
ratio is 1.3:1.  
HCC patients were in the age group ranging from 22 years to 75 years. 
Metastases patients were in the age group ranging from 28 to 85 years. 
Hemangioma patients were in the age group ranging from 30 to 70 years. Out 
of 63 patients, 7 patients were in the age group of 20 to 40 years, 40 patients 
were in the age group of 40 to 60 years, 16 patients were in the age group of 
above 60 years.  
In HCC, out of 25 patients, 9 patients presented with abdominal pain, 9 
patients with ascites, 4 patients with hepatomegaly and 3 patients with 
constitutional symptoms.  In metastases, out of 15 patients, 4 patients presented 
with abdominal pain, 3 with hepatomegaly, 3 with ascites, 3 patients presented 
with no symptoms and 2 patients with constitutional symptoms. In 
hemangioma, out of 23 patients, 20 patients had no symptoms and 3 patients 
presented with abdominal pain.    
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Out of 88 lesions in total, 71 lesions were located in the right lobe and 17 
lesions were located in the left lobe. Out of 15 metastatic patients 4 patients had 
metastases from carcinoma stomach, 3 had colorectal carcinoma, 3 had breast 
and lung carcinoma respectively, and 2 patients had carcinoma ovary.   
Out of 30 lesions of HCC, 15 lesions were mixed appearance in gray 
scale ultrasound, 9 lesions are hyperechoic and 6 lesions are hypoechoic. In 
metastases, out of 32 lesions, 11 lesions were hypoechoic, 9 lesions were 
isoechoic, 5 were hyperechoic, 4 calcified and 3 mixed appearance. Out 26 
hemangiomas, 21 lesions appear hyperechoic and 5 lesions were mixed 
echogenic in appearance.  
Out of 88 lesions, 41 lesions were less than 5 cm and 47 lesions were 
more than or equal to 5 cm. The mean size of HCCs (6.4cm) is significantly 
higher than that of metastases (3.6 cm) and hemangiomas (3.3 cm) (p<0.001) 
In 25 patients of HCCs, 22 had solitary lesions, 2 patients had 3 lesions 
and one patient had 2 lesions.  In 15 patients with metastases, 5 patients had 
single lesion, 3 patients had two lesions, 7 patients had 3 lesions. In 23 patients 
with hemangiomas, 20 patients had single lesion, 3 patients had 2 lesions.  
Colour Doppler sonogram findings in favour of HCC include pulsatile 
intralesional flow, intralesional PSV more than 40 cm/s, normal or minimally 
increased common hepatic artery flow and hepatic tumor index more than or 
equal to one. CDS findings in favour of metastases include pulsatile or 
continuous flow within the lesion with intralesional PSV less than 40 cm/s, 
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elevated common hepatic artery flow and Tumour Index(TI) less than one. 
CDS findings suggestive of hemangiomas include minimal continuous flow with 
intralesional PSV less than 40 cm/s, normal common hepatic artery PSV and TI 
less than one.  
On CDS, out 30 HCCs, 27 lesions showed pulsatile flow, 2 lesions 
showed continuous flow and one lesion showed no flow. In metastases, out of 32 
lesions, 15 lesions showed pulsatile flow, 14 continuous flow and 3 lesions 
showed no flow. In hemangiomas, 15 continuous flow, 6 no flow and 5 lesions 
showed pulsatile flow. The detection rate of pulsatile flow was significantly 
higher (p<0.01) in HCCs than in metastases and hemangiomas.  
Out of 88 lesions, 31 lesions showed intralesional peak systolic velocity 
(ILPSV) of 40 cm/s and above. In which, 25 were HCCs, 3 were metastases and 
3 were hemangiomas. Mean peak systolic velocity of HCC is 75.1 cm/s which is 
higher than that of metastases (24.1 cm/s) and hemangioma (19 cm/s) which is 
statistically significant (p<0.01). 
Mean peak systolic velocity obtained form common hepatic artery 
(CHAPSV) of metastases (108.4 cm/s) significantly exceeded that of HCCs (72.9 
cm/s) and hemangiomas (58.1 cm/s) (p<0.01). 
The hepatic tumor index (TI) calculated by dividing the intralesional 
PSV by common hepatic artery PSV. Hepatic tumor index was equal to or 
greater than one in 22 of 30 HCCs, one of 32 metastases and two of 26 
hemangiomas. The mean hepatic tumor index for HCC was significantly 
greater than those of metastases and hemangiomas (p<0.01 in both cases).  
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Combining intralesional pulsatile flow with PSV more than 40 cm/s with 
normal common hepatic artery flow velocity for detection of HCC, there is 
83.3% sensitivity, 89.7% specificity and 87.5% accuracy. Combining 
continuous or pulsatile flow with PSV<40 cm/s, with increased PSV of common 
hepatic artery for detection of metastases, there is 87.5% sensitivity, 94.6% 
specificity and 92.0% accuracy. Combining minimal continuous flow or no flow 
with intralesional PSV<40 cm/s, normal common hepatic artery PSV, there is 
84.6% sensitivity, 93.5% specificity and 90.9% accuracy for the detection of 
hemangiomas.  
When intralesional flow, ILPSV, common hepatic artery PSV and 
hepatic TI there is 83.3% sensitivity, 94.8% specificity and 90.9% accuracy for 
HCCs, 87.5% sensitivity, 98.2% specificity and 94.3% accuracy for the 
detection of metastases and for the detection of hemangioma there is 88.5% 
sensitivity, 87.1% specificity and 87.5% accuracy.  
The hepatic tumor index was more than or equal to one in 25 lesions (22 
HCCs, 1 metastases and 2 hemangiomas) and less than one in 63 lesions (8 
HCCs, 31 metastases and 24 hemangiomas) resulting in sensitivity of 88.0%, 
specificity of 87.3% and accuracy of 87.5%. 
On comparing to the Numata K, Tanaka K, Kiba T, Morimoto M et al37 
study in which a PSV of 40 cm/s or greater, with a hepatic tumor index equal to 
or greater than 1.0 was associated with a sensitivity of 91%, specificity of 83% 
and an accuracy of 89% in distinguishing HCCs from hepatic metastases, our 
study had 83.3% sensitivity, 94.8% specificity and 90.9% accuracy. 
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Wang WF, Zhang QP et al55 studied the use of CDFI in characterization 
of liver tumors. Their results showed Doppler flow signals could be detected in 
all hepatic carcinomas and 10 of 18 hemangiomas, with pulsatile flow in 41 of 
42 lesions and in 6 of 10 hemangiomas, with mean PSV obviously lower in 
hemangiomas (20.34 +/- 23.93) than HCCs (64.74 +/- 30.18). Our studied 
showed colour Doppler flow signals in 29 of 30 HCCs and 20 of 26 
hemangiomas. Out of which, pulsatile flow detected in 27 of 30 HCCs and 5 of 
26 hemangiomas. The mean PSV of HCCs 75.1 +/- 33.1 which is higher than 
that of hemangiomas 19.0 +/- 16.4. 
Kudo M, Tochio H, Zhou P et al24 study showed mean +/- SD of 
maximum velocity in hemangiomas (15.0 +/- 16.0 cm/s) was significantly lower 
than in HCCs (34.0 +/- 26.7 cm/s) and in metastases (37.9 +/- 17.4 cm/s). In our 
study the mean velocity of hemangiomas (19.0 +/- 16.4), HCCs (75.1 +/- 33.1) 
and metastases (24.1 +/- 15).        
On comparing  to Nino-Murcia M, Ralls PW, Jeffrey RB Jr, Johnson M 
et al36 in which 76% HCCs showed internal vascularity, 67% metastases and 
75% of benign lesions showed no internal vascularity, our study showed 96.7% 
HCCs showed flow and 9.4% of metastases and 11.4% of hemangiomas showed 
no flow.  
Yashura K, Kimura K, Ohto M, Matsutani S et al59 study showed 
presence of pulsatile flow in 35 of 55 HCCs, 7 of 25 metastases and continuous 
flow detected in 4 of 30 hemangiomas. On comparing to their study, our study 
showed pulsatile flow in 27 of 30 HCCs, 15 of 32 metastases and 5 of 26 
hemangiomas and continuous flow in 2 HCCs, 14 metastases and 15 
hemangiomas.  
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SUMMARY 
63 patients with 88 liver lesions referred by the Gastroenterology and 
Surgery Departments to our department for ultrasound and colour doppler 
sonography. 
Out of 63 patients, 36 patients were males 27 patients were females. 
Among 63 patients, 7 patients were between 20 to 40 years, 40 patients between 
40 to 60 years and 16 patients were above 60 years. 25 patients had HCCs, 15 
patients had metastases and 23 patients had hemangiomas. Out of 30 HCCs, 25 
were correctly identified by colour doppler ultrasound, 5 lesions were missed 
and 3 lesions were falsely identified as HCCs which turned out to be 2 
hemangiomas and one metastases on CECT, HPE. Out of 32 metastases, 28 
were correctly shown by doppler and 4 lesions were missed and one lesion was 
falsely diagnosed as metastases which on follow up turned out to be HCC.  Out 
of 26 hemangiomas, 23 were correctly shown by doppler, 3 lesions were missed 
and 8 lesions were mistakenly diagnosed as hemangiomas which on further 
follow up turned out to be 5 HCCs and 3 metastases. 
Sensitivity for colour doppler to differentiate HCC, metastases and 
hemangioma is 83.3%, 87.5% and 88.5%. Specificity to exclude the above 
lesions are 94.8%, 98.2% and 87.1%. So as to summarise, hepatocellular 
carcinoma, metastases and hemangiomas more than 2 cm are better 
characterized and reasonably differentiated with colour doppler ultrasound 
with good sensitivity and specificity.   
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CONCLUSION 
Colour doppler ultrasound is highly sensitive in evaluating common 
adult hepatic tumors more than 2 cm including hepatocellular carcinoma, 
metastases and hemangiomas.  
Pulsatile intralesional flow with peak systolic velocity more than 40 cm/s 
with hepatic tumor index more than or equal to one is diagnostic of HCCs. 
Intralesional pulsatile or continuous flow with intralesional PSV less than 40 
cm/s, increased common hepatic artery PSV with hepatic tumor index less than 
one is diagnostic of metastases. With intralesional continuous flow or no flow, 
intralesional PSV less than 40 cm/s, normal common hepatic artery PSV, 
hepatic tumor index less than one hemangiomas can be diagnosed with a 
reasonable degree of confidence.  
Finally we conclude that colour doppler sonography is readily available, 
relatively inexpensive, well tolerated, noninvasive tool with high diagnostic 
capability in differentiating common adult hepatic tumors (HCCs, metastases 
and hemangiomas) more than 2 cm.   
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ABBREVIATIONS 
CD   -      Colour doppler 
CDFI    -      Colour doppler flow imaging 
CDS   -      Colour doppler sonogram  
CECT    -      Contrast enhanced computed tomography 
CHAPSV   -      Common hepatic artery peak systolic velocity 
CT              -      Computed tomography 
CTA              -      Computed Tomographic angiography 
CTAP              -      Computed Tomographic arterio portography     
DUS              -      Doppler ultrasound  
FNAC              -      Fine needle aspiration cytology 
HCC              -      Hepatocellular carcinoma 
HPE              -      Histopathological examination 
ILF              -      Intralesional flow 
ILPSV             -      Intralesional peak systolic velocity 
MRI                -      Magnetic resonance imaging 
PET                 -      Positron emission tomography 
PSV                 -      Peak systolic velocity 
TACE   -      Transarterial chemoembolization 
TAE                 -      Transarterial embolization    
TI                      -      Tumor index 
US              -      Ultrasound 
USG          -      Ultrasonogram 
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DOPPLER EVALUATION OF COMMON ADULT HEPATIC TUMORS 
MORE THAN 2 CM IN COMPARISON WITH HPE AND CECT 
PROFORMA 
Name                          IP/OP NO: 
Age      Date 
Sex 
Occupation 
Address 
Presenting Complaints  
Abdominal pain 
Lump 
Loss of appetite, loss of weight 
Fever 
Ascites 
Jaundice 
Past History 
Cirrhosis 
HBV 
HCV 
H/O Primary 
Surgery 
Blood transfusion 
Personal History 
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Smoker  
Alcoholic 
Vaccination against HBV 
General Examination 
Anaemia 
Jaundice 
Lymphadenopathy 
Systemic Examination 
Hepatomegaly 
Splenomegaly 
Ascites 
Clinical Diagnosis 
Investigation 
AFP 
Gray scale ultrasound 
1)Lesion Size 
2)Shape    
3)Margins 
4)Number 
5)Location (right or left lobe, segments) 
6)Echogenicity 
7)Calcification 
8)Adjacent vessel involvement(portal vein thrombus) 
9)Bile duct dilatation 
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10)Liver echoes and architecture (cirrhotic liver) 
11)Regional lymphadenopathy 
12)Ascites 
Colour doppler ultrasound 
1)Intralesional flow pattern (pulsatile flow, continuous flow, basket pattern or 
spot pattern, central or peripheral flow) 
2)Intralesional peak systolic velocity 
3)Common hepatic artery peak systolic velocity 
4)Tumor index (intralesional PSV/common hepatic artery PSV) 
5)Portal vein involvement  
HPE and CECT 
Final conclusion 
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MASTER CHART 
S.NO. PATIENT NAME AGE SEX 
CLINICAL  
PRESENTATION 
 HCC 
1 MR.ELLAPPAN 75 1 2 
2 MR.YACOB 65 1 5 
3 MR.SUBBARAYAN 55 1 2 
4 MR.MANOHARAN 35 1 5 
5 MR.RAMASAMY 72 1 2 
6 MR.MARI 48 1 5 
7 MRS.SARASA 35 2 2 
8 MRS.CHANDRA 50 2 5 
9 MR.VENKATESAN 22 1 4 
10 MR.VARADHAN 55 1 3 
11 MR.SELVAM 49 1 5 
12 MR.RANGARAJAN 60 1 4 
13 MR.RAMASAMY 60 1 5 
14 MRS.KALIYAMMAL 55 2 2 
15 MRS.KUPPAMMAL 52 2 3 
16 MR.MURUGAN 49 1 2 
17 MRS.PENCILLAMMAL 52 2 5 
18 MRS.RATHINAM 60 2 4 
19 MR.KUPPUSAMY 52 1 5 
20 MR.MEYYIAPPAN 48 1 2 
21 MR.MUTHU 70 1 3 
22 MR.KARUPPAN 44 1 5 
23 MRS.CHINNAMMAL 48 2 4 
24 MR.ANTHONY 52 1 2 
25 MR.GOPAL 49 1 2 
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S.NO. PATIENT NAME AGE SEX 
CLINICAL  
PRESENTATION 
 METASTASES 
26.  MR.PERUMAL 65 1 1 
27.  MR.IBUNU 45 1 5 
28.  MR.PETHODAN 85 1 4 
29.  MRS.MARIAMMAL 55 2 1 
30.  MRS.CHINNAPILLAI 62 2 2 
31.  MR.SUBRAMANI 45 1 4 
32.  MR.MUNIRATHINAM 28 1 3 
33.  MRS.MURUGAMMAL 49 2 5 
34.  MRS.KONDAMMAL 62 2 2 
35.  MRS.KUMARIAMMAL 65 2 1 
36.  MRS.ANGELMARY 50 2 2 
37.  MR.MUNUSAMUY 65 1 4 
38.  MR.RANGASAMY 71 1 3 
39.  MRS.RATHINAMMAL 58 2 5 
40.  MR.MANI 50 1 2 
 HEMANGIOMA 
41.  MR.KALIMUTHU 70 1 1 
42.  MRS.KUPPAMMAL 60 2 1 
43.  MR.MURUGESAN 42 1 1 
44.  MR.SURIYANARAYANAN 40 1 1 
45.  MR.AYYAVU 52 1 1 
46.  MRS.SUBBAMMMAL 45 2 1 
47.  MRS.RAJI 42 2 1 
48.  MRS.VEDAVALLI 30 2 1 
49.  MR.KALIAPPAN 52 1 1 
50.  MRS.KANDAMMAAL 49 2 1 
51.  MR.MOORTHY 52 1 2 
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S.NO. PATIENT NAME AGE SEX 
CLINICAL  
PRESENTATION 
52.  MR.MU8NUSAMY 72 1 2 
53.  MRS.LAKSHMIAMMAL 59 2 1 
54.  MRS.CHINNATHAYI 52 2 1 
55.  MRS.LAKSHMI 35 2 1 
56.  MRS.THANGAMANI 49 2 1 
57.  MR.MARIAPPAN 60 1 1 
58.  MRS.GOVINDAMMAL 62 2 2 
59.  MR.KANDASAMY 62 1 1 
60.  MRS.MURUGAMMAL 52 2 1 
61.  MRS.KRISHNAVENI 68 2 1 
62.  MR.CHELLAPPAN 60 1 1 
63.  MRS.KANNIAMMAL 55 2 1 
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S.NO. SIZE(cm) LOCATION USG ILF ILPSV(cm/s) CHA  PSV(cm/s) TI D+E DEFG HPE/CECT 
HCC 
1. 5.2 1 5 3 80 68 2 1 1 1 
2. 6.3 1 5 3 70 65 2 1 1 1 
3. 4 1 3 3 95 73 2 1 1 1 
4. 5.4 1 5 3 65 55 2 1 1 1 
5. 7.2 1 1 3 110 84 2 1 1 1 
6. 7.8 1 5 3 85 75 2 1 1 1 
7. 6.4 2 5 3 98 85 2 1 1 1 
8. 3.7 1 3 3 129 94 2 1 1 1 
9. 6.3 1 1 3 55 62 1 1 1 1 
10. 6.2 2 5 3 60 60 2 1 1 1 
11. 4.8 1 5 3 73 65 2 1 1 1 
12. 6.7 1 5 3 34 52 1 2 3 1 
13. 8.3 2 3 3 120 95 2 1 1 1 
14. 5.6 1 3 3 113 120 1 1 1 1 
15. 5.4 1 1 3 30 64 1 2 3 1 
16. 4.6 1 5 1 0 55 1 3 3 1 
17. 9.1 1 1 3 120 100 2 1 1 1 
18. 8.2 1 5 3 76 65 2 1 1 1 
19. 5 1 3 3 68 62 2 1 1 1 
20. 7.9 2 5 2 12 68 1 3 3 1 
21. 5.8 1 1 3 49 65 1 1 1 1 
22. 4.9 1 5 3 76 65 2 1 1 1 
23. 6.1 1 3 3 84 77 2 1 1 1 
24. 7.3 1 5 2 18 45 1 3 3 1 
25. 7.8 1 1 3 110 96 2 1 1 1 
26. 10.2 2 5 3 114 102 2 1 1 1 
27. 6.4 1 3 3 89 75 2 1 1 1 
28. 7.1 1 3 3 79 65 2 1 1 1 
29. 4.9 1 3 3 69 63 2 1 1 1 
30. 6 1 5 3 72 68 2 1 1 1 
 113
S.NO. SIZE(cm) LOCATION USG ILF ILPSV(cm/s) CHA  PSV(cm/s) TI D+E DEFG HPE/CECT 
METASTASES 
31. 3.1 1 1 1 0 85 1 2 2 2 
32. 4.2 1 2 2 28 90 1 2 2 2 
33. 2.1 2 1 3 34 86 1 2 2 2 
34. 3.3 1 3 1 0 51 1 2 3 2 
35. 3.2 1 1 2 28 104 1 2 2 2 
36. 4.3 2 2 3 52 120 1 1 2 2 
37. 2.2 1 3 3 15 94 1 2 2 2 
38. 5.2 2 1 2 44 105 1 2 2 2 
39. 2.6 1 3 2 12 88 1 2 2 2 
40. 4.1 1 4 2 26 75 1 2 2 2 
41. 2.2 1 5 2 16 90 1 2 2 2 
42. 5.1 1 1 3 22 105 1 2 2 2 
43. 4.4 1 2 3 35 120 1 2 2 2 
44. 4.5 2 4 3 28 140 1 2 2 2 
45. 2.8 1 1 2 15 65 1 2 3 2 
46. 4 1 2 2 22 114 1 2 2 2 
47. 4.2 1 1 2 11 95 1 2 2 2 
48. 2.3 1 1 2 24 130 1 2 2 2 
49. 4.6 2 2 3 56 175 1 1 2 2 
50. 6.3 1 3 3 37 144 1 2 2 2 
51. 3 1 1 1 0 45 1 3 3 2 
52. 4.4 1 1 3 62 48 2 1 1 2 
53. 5.3 2 1 2 14 114 1 2 2 2 
54. 3.1 1 2 2 8 96 1 2 2 2 
55. 2.1 1 5 3 22 124 1 2 2 2 
56. 3.7 2 2 3 18 145 1 2 2 2 
57. 3.9 1 4 3 32 128 1 2 2 2 
58. 3.2 1 3 2 19 96 1 2 2 2 
59. 3.8 1 2 3 24 133 1 2 2 2 
60. 3.7 2 2 3 32 195 1 2 2 2 
61. 2.5 1 4 3 22 166 1 2 2 2 
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S.NO. SIZE(cm) LOCATION USG ILF ILPSV(cm/s) CHA  PSV(cm/s) TI D+E DEFG HPE/CECT 
62. 2.9 1 5 2 14 103 1 2 2 2 
HEMANGIOMA 
63. 2.2 1 3 2 8 55 1 3 3 3 
64. 3.1 1 5 2 12 86 1 2 3 3 
65. 3.2 1 3 1 0 52 1 3 3 3 
66. 2.8 1 3 2 9 62 1 3 3 3 
67. 2.2 1 3 3 45 65 1 1 2 3 
68. 4.6 1 3 1 0 60 1 3 3 3 
69. 3.1 1 3 2 18 55 1 3 3 3 
70. 2.8 1 3 3 58 52 2 1 1 3 
71. 3.2 1 3 2 22 59 1 3 3 3 
72. 4.1 2 3 2 14 62 1 3 3 3 
73. 2.3 1 3 1 0 56 1 3 3 3 
74. 3.1 1 5 2 22 64 1 3 3 3 
75. 4.2 1 3 2 28 61 1 3 3 3 
76. 6.4 1 3 3 59 45 2 1 1 3 
77. 2.7 2 5 2 28 62 1 3 3 3 
78. 4.3 1 3 2 11 55 1 3 3 3 
79. 2.8 1 5 1 0 45 1 3 3 3 
80. 2.5 2 3 2 17 52 1 3 3 3 
81. 5.2 1 3 2 22 51 1 3 3 3 
82. 2.6 1 3 1 0 49 1 3 3 3 
83. 2.9 1 3 1 0 62 1 3 3 3 
84. 3.1 1 3 3 28 65 1 3 3 3 
85. 2.4 2 5 3 32 69 1 3 3 3 
86. 3.1 1 3 2 21 54 1 3 3 3 
87. 2.4 1 3 2 18 56 1 3 3 3 
88. 4.2 1 3 2 22 57 1 3 3 3 
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KEY TO MASTER CHART 
1) Location 
        Right lobe - 1 
        Left lobe - 2 
2) USG 
        Hypoechoic - 1 
        Isoechoic      - 2 
        Hyperechoic    - 3 
        Calcified                     - 4 
        Mixed                          - 5 
3) ILF (Intra lesional flow) 
        No flow                      - 1 
        Continuous flow         - 2 
         Pulsatile flow             - 3  
4) TI (Tumor index) 
          Less than one            - 1 
          Greater than or  
                           equal to one            -  2 
5) HPE/CECT 
        HCC                              - 1 
        Metastases                     - 2 
6) Sex 
        Male                             - 1 
        Female                          - 2 
7)Clinical Presentation 
        Asymptomatic                - 1 
         Abdominal pain             - 2 
         Constitutional symptoms         - 3   
         Lump                              - 4 
         Ascites            
 
